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ABSTRACT 
 
 
The role of obesity in regulation of microRNA (miRNA) expression in distal and 
proximal colon was assessed: 1) isolation and quantification methods for miRNAs were 
established in rat liver tissue; 2) miRNA expression patterns were compared using 
miRNA PCR arrays in lean proximal and distal colonic tissue; and 3) the influence of 
obesity on miRNA expression in these colonic regions was investigated by screening 
cancer miRNA coding genes in colonic mucosal samples from Zucker obese and lean 
rats. Up-regulation of 20 miRNAs was observed in obese liver tissue.  Colonic mucosal 
miRNA expression patterns and abundance differed for distal and proximal colonic 
regions in both lean and obese tissue.  Obesity exerted a profound region-specific effect 
on miRNA expression patterns and levels indicating biologically distinct tissue in distal 
and proximal colon.  Obesity markedly affects miRNA gene regulation, and miRNA is a 
key molecular player in the genesis of colon cancer.  
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CHAPTER1 
INTRODUCTION 
 
Overview 
Development of colon cancer is a complex multistep process involving sequential 
clonal selection and propagation of transformed cells.  It is recognized that there are 
multiple players which orchestrate the important events in the life of a transformed 
cells. These players include host’s physiological state and interaction of the 
transformed cells with the normal surrounding cells of the host organ as well other 
organ systems. The complex orchestrated events allow the transformed cells to either 
complete their life cycle and emerge as tumor or lead to premature death. 
It is recognized now that the term “colon cancer” is normally used to represent 
multiple cancer sub-types based on the mutational spectra of the cancers and their 
morphology. Ample evidence exist to support the concept that colon is not a single 
organ and that proximal (right sided colon) and distal colon (left sided colon) are 
embryologically and physiologically different. Subsequently, the tumors appearing in 
these regions are also biologically different. A majority of these evidences are from 
epidemiological and clinical studies. A limited exploration has been conducted in 
animal models.   
Our ability to dissect the process of colon carcinogenesis at the molecular level has 
added a number of new molecular players, miRNA being prominent among them. 
miRNAs or miRNAs are known as the master regulators of  genes involved in normal 
functioning of the cell as well as pathogenesis of cancer. Hence the study of their 
functioning and regulation in normal versus tumor cell is important for identification 
of new molecular targets in cancer preventive therapies. 
Obesity is linked to heightened risk of colon cancer. In our laboratory we have used 
the Zucker obese (Zk-Ob) rats as a model to study the link between obesity, 
metabolic syndrome-X and colon cancer. In this model, tumors mainly appear in the 
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distal colonic regions however, a number of tumors also appear in the proximal 
colonic regions. Now it is known that several miRNAs are associated with 
inflammation and associated diseases like colitis, rheumatoid arthritis, 
atherosclerosis, allergic airway inflammation. In our laboratory, we are interested to 
develop animal model of carcinogenesis focusing on the biology of the tumors. The 
purpose of this research was to establish the method of miRNA isolation and to 
quantify their expression levels in rat colon under obese conditions. We used the 
Zucker obese (Fa/fa) and lean (fa/fa) rats as model system.  
 
Hypothesis 
The hypothesis which provides the basis of this dissertation is that obese state will 
influence the composition and expression levels of miRNAs in the colons of Zucker rats. 
During this investigation it was of interest to further determine if obesity known to 
heighten the risk of colon cancer will influence miRNA expression in distal versus 
proximal colon. This hypothesis is based on the fact that the clinical tumor samples from 
proximal colon exhibit different mutational spectra than those from distal colon. We have 
recently published that in Zucker obese rats, the molecular feature of the tumors 
appearing in proximal colon also differ from those that appear in the distal regions. We 
speculated that the ability of proximal and distal colonic regions to respond to DNA 
damage and repairs as well as sustain the growth of transformed cells with specific 
mutations depends on the biology of the host  tissue. 
Specific aims of research 
 Aim 1: To establish the method of isolation and quantification of miRNAs in rat 
tissue (liver). 
Aim 2: To determine if obesity influences miRNA expression level and pattern in 
distal and proximal regions of the colon. 
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To meet the specific aim 1 we used liver tissue from Zucker obese and lean rats. . To 
meet the aims 2 we assessed the expression levels of miRNA in lean rats and compared 
the expression pattern in the distal and proximal colonic regions. This study was followed 
by the assessment of miRNAs in obese rat colonic tissues by the regions. To put this 
dissertation in proper perspective a background information on colonic structure and 
anatomical differences between the distal and proximal colonic regions, development of 
colon cancer, link between obesity and colon cancer and role of miRNAs structure and 
function are provided. For brevity the key information is provided with specific 
references.  
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CHAPTER 2 
REVIEW OF LITERATURE 
 
 
Colon  
The large intestine or the colon is a muscular tubular organ about 1.5 meters in 
length which represents the terminal part of the gastro-intestinal tract. The colon 
consists of the caecum (with an attached appendix), ascending, transverse, 
descending and sigmoid components ending with the rectum. Primary functions of 
the colon involve processing of waste material, reabsorption of water and nutrients, 
and mucous production.(Arthur F. Dalley 1999). 
 
Histologically, the colon has four distinct layers: innermost mucosa, sub mucosa, 
muscularis externa and outermost serosa. (Arthur F. Dalley 1999) (Figure1.1). The 
innermost mucosal layer consists of invaginations known as crypts lined with colonic 
epithelium. Unlike the small intestine, colonic crypts have no villi for nutrient 
absorption. Crypts are supported by the lamina propria consisting of connective 
tissue, blood vessels, and immune cells including lymphocytes and macrophages. 
(Arthur F. Dalley 1999) The mucosal layer is the most common origin for colon 
cancers. 
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Figure 1.1 Structure of colon. The colon or the large intestine is a hollow, muscular 
and tubular organ with four layers: the innermost mucosa, sub mucosa, muscularis 
externa and outermost serosa. The innermost mucosal epithelium has invaginations 
called ‘colonic crypts’ which are the site of origin of colon cancer. (adapted and 
modified from Yi-Ben Chen, updated 2010) 
 
Right and left side of colon   
Embryologically, the colon develops partly from the midgut (ascending colon to 
proximal transverse colon) and partly from the hind gut (distal transverse colon to 
sigmoid colon). (Figure1.2) The ascending colon which lies vertically on the right 
side of the splenic flexure, is also referred to as the ‘proximal’ colon. The transverse 
colon again takes a right-angled turn just below the spleen (splenic flexure) and 
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becomes the descending (left) colon, which lies vertically in the most lateral left part 
of the abdominal cavity. 
 
Figure 1.2 Colon anatomy. Colon has been divided into three parts depending on its 
location with respect to splenic flexure. On right side of the splenic flexure is the 
ascending colon also known as ‘proximal’ colon and on the left side of the splenic 
flexure is the descending colon also known as the ‘distal’ colon. Transverse colon 
runs horizontal. 
 
Colonic epithelium is a highly diverse and dynamic system involving constant cell 
renewal. (Ding, Ko et al. 1998). Continuously proliferating stem cells situated at the 
base are responsible for replenishing the entire epithelium every 3-8 days.(Cotran 
R.S. 1999) This cell regeneration occurs within the basal two-third portion of the 
crypt. As the cells migrate upwards they differentiate into specialized cell types 
including absorptive, mucous secreting, endocrine, and anti-bacterial protein 
secreting Paneth cells. (Radtke and Clevers 2005; Schneikert and Behrens 2007) 
(Figure 1.3) 
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Figure 1.3 Differentiation of colonic epithelium. The colonic epithelium has 
invaginations called crypts which have a population of stem cells at the base that give rise 
to actively dividing precursors. These precursor cells migrate to the top of the colon and 
and differentiate as enterocytes (absorptive cells), entero endocrine (hormone secreting 
cells), goblet cells (mucus secreting cells) and paneth cells (antimicrobial toxin secreting 
cells) ( adapted and modified from Jean Schneikert, Jurgen Behrens, Gut 2007) 
 
Colorectal Cancer  
 
Colorectal cancer (CRC) is the 3rd most common malignancy and 4th most common 
cause of cancer related mortality worldwide. (Tenesa and Dunlop 2009) It happens to 
be the 2nd leading causes of cancer related deaths in the United States and other 
developed countries, despite considerable advances in diagnosis and treatment 
techniques.(Jemal, Murray et al. 2005; Jemal, Siegel et al. 2009). It alone accounts 
for 11% of worldwide cancer cases, preceded only by prostate, lung and breast 
cancer. In addition, it is estimated that 50% of the population will develop an 
adenomatous polyp by the age of 70. (Jemal, Murray et al. 2005) 
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Approximately, 20% of  CRC cases have a familial basis, (Rustgi 2007) where some 
are associated with well-defined syndromes, such as hereditary non polyposis 
colorectal cancer (HNPCC) and familial adenomatous polyposis (FAP). However, 
majority of the CRC cases have been linked to environmental factors and food borne 
mutagens, specifically intestinal microflora including pathogens and chronic 
intestinal inflammation, which predisposes tumor formation.  
 
CRC is multistep, multi factorial disease that involves the clonal  selection  and 
clonal propagation of initiated colonic epithelial cells, which progress from normal 
to precancerous to malignant states over a span of 5-40 years.(Harris 1991; Roncucci 
L. 1991.; Lei Cheng 2003 December) . The sequential events of colon carcinogenesis 
concerning genetic and phenotypical changes are very well characterized by the 
adenoma-carcinoma model first described by Fearon and Vogelstein (1990). 
According to this model, CRC is caused by accumulation of mutations in the 
classical oncogenes and tumor suppressors genes, which correspond to a sequential 
transition of single pre-neoplastic cell to aberrant crypt foci (ACF) and then to 
adenoma and metastatic carcinoma. (Figure 1.4) The earliest molecular alteration in 
this pathway is mutation in the adenomatous polyposis coli (APC) tumor suppressor 
gene which is a component of the Wnt signaling pathway. This is followed by 
mutation in the KRAS and TP53, in the larger adenomas and invasive carcinoma. 
(Fearon and Vogelstein 1990) This pathway is referred to as the ‘APC pathway’ or 
the ‘chromosomal instability (CIN) pathway’ because the colorectal tumors arising 
by this pathway are characterized by gross chromosomes abnormalities including 
deletions, insertions, and loss of heterozygosity. Another molecular pathway 
proposed is the DNA mismatch repair pathway.(Aaltonen, Peltomaki et al. 1993) The 
key element of this pathway is mutation in the DNA repair enzymes e.g MLH1, 
MSH2, which results in accumulation of mutations in the microsatellite regions of 
the genome. (H Iino 2000 July) This results in microsatellite instability in the tumors 
arising from this pathway and hence it is also called microsatellite instability (MSI) 
pathway. 
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Figure 1.4 Fearon–Vogelstein model of colon carcinogenesis. The sequential events of 
colon carcinogenesis concerning genetic and phenotypical changes are very well 
characterized by the adenoma-carcinoma model first described by Fearon and Vogelstein 
(1990) 
 
   
Evidences indicating that adenomas might not be the only CRC precursor began to 
emerge in 1990. Longacre and Fenoglio - Preiser studied a group of polyps that 
showed mixed histology of both hyperplastic and adenomatous polyps.(Longacre TA 
1990) These lesions had glands with serrated appearance and showed nuclear 
features of adenomas, hence they were called serrated adenomas. The adenoma 
carcinoma pathway for serrated polyps is different from the traditional CIN or MSI 
pathway. For e.g- APC and TP53 mutations are rare, whereas alterations in 
microsatellite sequence and hypermethylation of CpG islands are more common. 
There are two overlapping pathways for development of serrated lesions.  The first 
one is more common in the right sided colon (proximal) and is characterized by high 
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level of MSI and CpG island methylation  and BRAF mutation.(Spring, Zhao et al. 
2006) The second one is more common in left sided colon (distal) and shows 
microsatellite stability (MSS) or low grade of MSI (MSI-L) and also show mutations in 
KRAS. (Jass, Whitehall et al. 2002) 
Obesity associated inflammation and colon cancer 
Obesity is a chronic inflammation state and a rising epidemic in North America, with 
both environmental and  genetic etiological factors.(Formiguera and Cantón 2004) 
The connection between obesity and risk of colon cancer is well established and has 
a great deal of supporting evidence from genetic, pharmacological and 
epidemiological data. (Rapp, Schroeder et al. 2005). While the biochemical and 
molecular links between the two physiological disorders are still under review, the 
interconnected roles of insulin  resistance , adipose tissue  and inflammation are well 
documented in literature. (Figure 1.5) Key mediators of inflammation-induced cancer 
include nuclear factor kappa B (NFκB), reactive oxygen and nitrogen species 
(RONS), inflammatory cytokines, chemokines, adhesion molecules and specific 
miRNAs. Chronic inflammation predisposes cells for oncogenic transformation by 
inducing genomic instability, increasing cell proliferation and angiogenesis, altering 
the genomic epigenetic state. 
Physiological parameters linking obesity and cancer 
Obesity or chronic inflammation state is often encountered with high levels of 
glucose, triglycerides, cholesterol in the blood plasma due to inactivity of the insulin 
hormone or its receptor. Insulin resistance implies a cells inability to respond to 
normal levels of insulin, thus requiring abnormally high amounts of  insulin hormone 
for glucose metabolism. This condition further leads to irregular triglycerides, fatty 
acids and glucose levels, all metabolic aberrations that also correlate with an 
increased risk of colorectal cancer.(Gunter and Leitzmann 2006). There are 
convincing evidences that suggest the connection between obesity and colon cancer 
risk in three possible ways. (reviewed by Gunter and Leitzmann 2006) The first 
being the fact that insulin hormone is a growth factor which is known to promote cell 
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growth and proliferation. Hence, the exposure of high levels of insulin to parts of the 
body that are not accustomed to it e.g- colon, can interfere with the normal cell 
signaling and promote cell proliferation. (Gunter and Leitzmann 2006) This has been 
experimentally proved by Kiunga et al 2004, who reported the presence of high 
levels of insulin and insulin receptor in colon tumor cells compared to normal 
mucosa. Secondly, an insulin resistant state also promotes high levels of circulating 
insulin-like growth factor (IGF), which can also promote colonocyte division and 
block apoptosis by receptor binding. (Giovannucci 2001) Increased IGF-1-receptor 
(IGF-IR) also stimulates cell division in intestinal epithelial cells (Ma J. 1999) and 
several epidemiological studies have shown positive correlation between IGF and IGF-IR 
levels and colon cancer risk.(Komninou, Ayonote et al. 2003) Finally, the high 
circulating plasma glucose and  lipids associated with insulin resistance serve as a 
reservoir for reactive oxygen species (ROS) generation, known contributors to 
carcinogenesis. High visceral abdominal fat found in obese individuals is especially a 
critical source for ROS. (Furukawa, Fujita et al. 2004; Frezza, Wachtel et al. 2006) 
Along with oxidative stress, increased amount of fat tissue promotes a pro-
inflammatory environment, also strongly correlates with increased cancer risk. 
Cytokines/adipokines such as tumor necrosis factor-α (TNF-α) are readily secreted 
by adipocytes and further enhance inflammation, insulin resistance, impaired glucose 
metabolism and ROS production. (Furukawa, Fujita et al. 2004; Sonnenberg G.E. 
2004.) 
Leptin, which is also known as the hormone of satiety, has been implicated in obesity 
associated colon cancer. Though its role is not very clear, it has been shown to 
accelerate HT-29 cell proliferation and promote ACF formation in vivo.(Liu Z 2001.) 
Interestingly, F344 rats administered with continuous high dose of leptin have shown 
reduction in the number of ACF compared to controls. (Aparicio, Guilmeau et al. 
2004)  Leptin secreted from adipose tissue has also been shown to enhance insulin 
resistance. (Matsuzawa 2006) 
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Metabolic Syndrome X 
Many of the physiological abnormalities associated with obesity or insulin resistance 
are collectively referred to as Metabolic syndrome, or syndrome X. It is a term given 
by Reavan in 1988, to the physiological disorders associated with obesity, 
specifically abdominal/visceral obesity. Although there are contradicting views 
regarding the inclusion of insulin resistance and dyslipidaemia (including 
hypercholesterolemia and hypertriglycerolemia) in this syndrome, hyperglycemia 
and hypotension have been unanimously included in this category.(Shaw, Hall et al. 
2005; Sorrentino 2005). These symptoms or abnormalities have been associated with 
diabetes, atherosclerosis and cancer. 
Oncogenic mechanisms associated with inflammation 
Prolonged inflammation can induce DNA mutations and contribute to genomic 
instability in more than one ways. (Perwez Hussain and Harris 2007; Colotta, 
Allavena et al. 2009) Free radicals (RONS), produced during inflammation can 
reduce the expression and enzymatic activity of the critical DNA repair enzymes eg. 
mut S homolog 2 and 6. It can further cause increased expression of DNA 
methyltransferases that can cause global hypermethylation of the genome. The 
downstream effect of this includes silencing of DNA mismatch repair enzymes (eg- 
hMLH1 and hSMH2) and several tumor suppressor genes (eg- APC, CDKN 2, 
BRCA1,Rb and MDM2) by promoter methylation. (Fleisher, Esteller et al. 2000; Das 
and Singal 2004) 
 Molecular mediators common to inflammation and cancer  
Inflammation can induce cancer by both extrinsic and intrinsic pathways. In extrinsic 
pathway, chronic inflammation itself is the driving force, whereas in intrinsic 
pathway, the genetic alteration of oncogenes and tumor suppressors as well as 
various inflammatory mediators play an important role in carcinogenesis. The 
inflammatory mediators include the cytokines, chemokines RONS, COX-2 and 
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NFκB. For eg- a dominant mutation in Ras proto-oncogene, can induce inflammatory 
response through induction of pro-inflammatory cytokines interleukins (ILs)  IL1, 
IL6 and IL11 and the chemokine IL8, which aid in Ras mediated oncogenesis. (Bos 
1989) Ras also induces IL-8 that mediates tumorigenesis and angiogenesis. 
(Sparmann and Bar-Sagi 2004) Genetic mutations stimulate the tumor cells to 
produce inflammatory cytokines and free radicals, which creates a feedback loop 
where the tumor cells recruit inflammatory cells that can produce additional 
cytokines and free radicals to the site of tumor  that can aid tumorigenesis. (Figure 
1.5) 
Some of the key players are described in detailed in the following sections: 
Nuclear Factor Kappa B 
Nuclear factor kappa B or NFκB as it is commonly called is a transcription factor 
and key mediator of inflammation induced carcinogenesis. (Shen and Tergaonkar 
2009) Under normal condition, NFκB is bound to its negative regulator also called 
the inhibitor of kappa B (IκB) and stays inactive in the cytoplasm. Following an 
inflammation stimulus, IκB kinase phosphorylates IκB and targets it for proteosomal 
degradation. Activated NFκB translocates to the nucleus where it drives the 
transcription of its target genes, many of which are inflammation related eg-
cytokines and chemokines, nitric oxide synthase (NOS) , cyclooxygenase (Cox-2) 
and tumor necrosis factor (TNF)α.(Naugler and Karin 2008) 
 
NFκB creates a protumorigenic environment by turning on the expression of 
following set of genes: 
1.) Cell cycle related genes eg c-Jun-N-terminal kinase that increase cell 
proliferation  
2.) Vascular endothelial growth factor (VEGF) and angiopoetin that stimulate 
angiogenesis 
3.) Bcl2, Bcl-xL, and cFLIP that makes cell resistant to apoptosis and necrosis. 
4.) Pro-inflammatory cytokines, chemokines and adhesion molecules. 
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Inflammatory bowel disease (IBD) which is associated with colitis associated cancer 
(CAC), show persistant activation of NFκB in the myeloid and epithelial cells of 
colonic mucosa. (Rogler and Andus 1998; Chung 2000) 
 
Reactive oxygen and nitrogen species (RONS) 
 
These are highly reactive free radicals produced by inflammatory cells, collectively 
known as the reactive oxygen and nitrogen species (RONS). They have the ability to 
induce DNA strand breaks, mutations and aberrant cross linking, causing genomic 
instability. Chronic inflammation results in elevated levels of RONS that causes 
oxidative and nitrosative stress that contributes to tumorigenesis. (Hussain, Trivers et 
al. 2004; Hofseth 2008)  In colitis associated cancer (CAC), chronic inflammation 
causes oxidative damage to DNA, leading to the p53 mutations observed in tumor 
cells.(Choi, Yoon et al. 2002; Kraus and Arber 2009). ROS can also directly oxidize 
and inactivate mismatch repair enzymes at protein level. (Choi, Yoon et al. 2002; 
Hussain, Hofseth et al. 2003; Kraus and Arber 2009). Nitrogen oxide (NO) is a 
reactive free radical produced in large amounts by the inducible nitric oxide synthase 
2 (NOS2) under conditions of chronic inflammation. In its pro-tumorigenic role, NO 
induces DNA strand breaks, promotes angiogenesis by induction of VEGF and 
increases cell proliferation and invasion. (Hussain, Trivers et al. 2004). In its anti-
tumorigenic role, NO can cause cytotoxic cell death of malignant cells and modulate 
the immune system to eradicate the cancerous cells. There is a negative loop between 
NO and tumor suppressor protein 53 (TP53), where NO causes the stabilization and 
accumulation of TP53 which induces apoptosis, cell cycle arrest in the malignant 
cells and represses levels of NO. (Forrester, Ambs et al. 1996; Ambs, Ogunfusika et 
al. 1998). 
 
Cytokines and chemokines 
 
Cytokines are signaling molecules that are key mediators of inflammation or an 
immune response. Upon binding to their receptor, they trigger a signaling pathway 
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that leads to cell proliferation, apoptosis, angiogenesis and cellular senescence. They 
broadly fall under two categories 1.) Pro-tumorigenic and 2.) Anti-tumorigenic. The 
pro-tumorigenic cytokines include IL1, IL6, IL15, IL17, IL23 and tumor necrosis 
factor α (TNFα) , whereas the anti-tumorigenic cytokines include IL4, IL10, IL13, 
transforming growth factor (TGFβ) and interferon (IFN α). In case of CRC and CAC, 
the role of IL-6, IL-1 and TNF-α in tumorigenesis has been well studied. (Tang, 
Katuri et al. 2005; Popivanova, Kitamura et al. 2008; Wang, Liu et al. 2009). IL-6 is 
a potent stimulator of colon cancer cell proliferation and tumor growth. (Becker, 
Fantini et al. 2005) It has been implicated in pro-tumorigenic activity for many 
cancers and has been found to be required for CAC in mouse models. (Grivennikov, 
Karin et al. 2009) TNFs are produced during early inflammation; they trigger 
production of other cytokines, chemokines and endothelial adhesion 
molecules.(Balkwill 2009; Li, Vincent et al. 2009).TNF-α expression increases 
during colon carcinogenesis which further confirms its role in inflammation, 
angiogenesis and tumor promotion. (Popivanova, Kitamura et al. 2008). One of the 
key functions of TNF-α is to activate the pro-inflammatory transcription factor 
NFκB. The anti inflammatory cytokines like IL-10 and TGF-β , have a general role 
in tumor suppression. IL-10 exerts its anti-tumorigenic effect by down-regulating  
NFκB, which results in low levels of pro-inflammatory cytokines eg- IL-6, IL-12 and 
TNF-α. (Zhang 2008 December) TGF-β is another anti-inflammatory cytokine that 
suppresses tumor growth by inhibiting proliferation,  promoting apoptosis,  
stimulating the release of anti-inflammatory cytokines and suppressing the 
expression of pro-tumorigenic cytokines.(Yang and Moses 2008) Mutation in TGF-β 
pathway within epithelial cells predisposes to or facilitates colonic tumor 
development and growth.  
Chemokines are a class of cytokines that recruit leukocytes at the site of 
inflammation. They are released by the inflammatory cells after the initial 
stimulation by the cytokines. Tumors generally show high levels of chemokines that 
recruit leukocytes to the site of tumor, creating a pro-inflammatory and pro-
tumorigenic environment. 
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Chemokines and adhesion molecules 
Early feature of inflammation is the release of chemokines like Monocyte 
chemoattractant protein (MCP). These factors increase the expression of interstitial 
and vascular cellular adhesion molecules like Interstitial Cellular Adhesion 
Molecules (ICAM) and E-selectin that attract monocytes and immune cells. 
Chemokines like MCP also induce the proliferation and pro-inflammatory gene 
activation producing cytokines like IL-1α, IL-6, IL-18 etc. Other factors that 
stimulate gene expression of pro-inflammatory cytokines in obese state are RONS, 
oxidized lipids, free fatty acids.  
    
 
 Figure 1.5 Schematic diagram showing pathways linking obesity to cancer. 
Insulin resistance and insulin like growth factor (IGF) are one of the several links 
between obesity and cancer. High levels of circulating insulin up-regulates growth 
hormone (GH) that induces hepatic production of  IGF-1. IGF-1can inhibit apoptosis 
and stimulate cell proliferation through several downstream signaling networks , 
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including the phosphatidylinsitol3-kinase (PI3-K)-AKT system and the 
Ras/Raf/mitogen activated protein kinase (MAPK) systems, respectively. Leptin, 
also secreted by adipocytes has mitogenic effects and anti apoptotic effects through 
MAPK and PI-3-Kinase pathways. Adiponectin exerts anti-carcinogenic effect 
through AMP activated protein kinase (AMPK) through receptors AdipoR1 and 
AdipoR2. Adipopectin regulates growth arrest and apoptosis through p53 and p21. 
IL-6 and TNF-α are the two major inflammatory cytokines that are elevated in 
obesity. They exert pro-tumorigenic effect by increasing cell survival and cell 
proliferation through activation of NF-κB 
Animal Model 
Preclinical or animal models provide a system to study the biological process of a 
disease in a physiological state relevant to human beings. They provide valuable 
preliminary data upon which human clinical trials can be based. However, they 
should always be evaluated with regards to how relevant they are to human 
conditions, and how predictive they can be for the disease process. (Green and 
Hudson 2005) 
With regards to colon carcinogenesis, molecular and pathological similarities to the 
human condition should be observed in order to have an effective model.(Reddy 
2004) Currently the APC min+/-
 
mouse and azoxymethane rat model are the two main 
animal models used to study the effect of dietary supplements on colon cancer. 
Zucker obese rats, traditionally used to study obesity and related metabolic disorders, 
offer a novel way of studying the progression of colon cancer in an altered 
physiological state. 
 
Zucker-Obese Animal Model 
 
Zucker obese (Zk-Ob) rats are an excellent model of human obesity, and provide an 
ideal opportunity to study colon carcinogenesis in an altered physiological state. The 
Zucker or ‘fatty’ rat was developed in the laboratory of  Zucker and Zucker  in 1961, 
by spontaneous mutation in a single recessive gene (Fa  allele is designated as 
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normal, while  fa is the fatty mutation). Zk-Ob rats inherit obesity as  an autosomal 
Mendelian recessive trait, fa/fa homozygous for nonfunctional leptin receptors, in 
comparison to their lean (Fa/fa or Fa/Fa) counterparts.(A. 1977.)  Leptin is a peptide 
hormone produced by adipocytes that regulates body weight and fat metabolism by 
sending signals to the hypothalamus to suppress apetite.(Arthur F. Dalley 1999) In 
Zk-Ob rats, obesity is associated with metabolic dysfunction of fat metabolism 
characterized by latescence and increased adipose tissue formation. (Zucker T.F. 
1962. ) Genetic association of Fa gene to obesity is confirmed as Zk-Ob rats on low 
fat or energy restricted diet also exhibit these symptoms. Interestingly, female 
Zucker rats are sterile, which has implications for breeding programs.   
 
Average weights of these animals at 40 weeks is  800g and 625g for Zk-Ob, and 
480g and 295g for Zucker lean (Zk-Ln), males and females respectively.(Zucker T.F. 
1962. ) Zk-Ob rats exhibit hyperphagia, hypertriglyceridemia, hypercholesterolemia, 
hyperinsulinaemia and mild hyperglycemia at about six weeks of age. Pathological 
findings at death often include hydronephrosis and polycystic kidneys, as well as 
fatty livers.(Zucker T.F. 1962. ) It has been shown that Zk-Ob rats are more sensitive 
to chemically induced colon carcinogenesis in comparison to their lean 
counterparts.(Raju and Bird 2003) Since there is little difference in ACF number 
between Fa/fa and Fa/Fa animals, the recessive gene linked to leptin receptor 
deficiency is not solely responsible to higher susceptibility of colon cancer.(Weber, 
Stein et al. 2000) Use of this animal model helps understanding carcinogenesis in 
relation to obesity and associated metabolic disorders, providing valuable 
information for treatment and prevention strategies. 
  
           Micro-RNA 
  
 
           Brief introduction 
 
Micro RNAs (mi RNAs) are 19-22 nucleotide long single stranded non protein 
coding RNAs that act as guide molecules in post transcriptional gene silencing by 
base pairing with target mRNA leading to its cleavage or translational 
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repression.(CULLEN 2003; Bartel 2004; VICTOR AMBROS 2008). With >200 
members per species in higher eukaryotes, miRNAs form one of the largest gene 
families accounting for approx 3% of the genome and targeting 30% of coding 
regions of the genome (Lewis, Shih et al. 2003; Bartel 2004). Since their discovery 
back in 1993 by Victor Ambros and colleagues, who identified the first miRNA 
targeting lin-4 gene in C.elegans, miRNAs have come a long way in being 
recognized as a major player in post transcriptional gene regulation. Even though we 
are far from unraveling the complex role of miRNAs in gene regulation, it is evident 
that they have important role in almost all biological process known, including 
developmental timing, growth control, differentiation and apoptosis. Accordingly, 
altered miRNA expression can have serious implication on the regular metabolism of 
the cell and be a potential cause for diseases like cancer. 
 
Gene Structure and miRNA gene transcription 
Location in the genome  
Early annotation to find out the genomic position of miRNAs indicated that most 
them are located in the intergenic regions , although a sizeable minority are found in 
the intronic region of known genes in sense or anti sense orientation.(Lau, Lim et al. 
2001; Kim 2005) This implied that most of the miRNAs are transcribed as 
autonomous replication unit with their own promoter. Approximately 50% of the 
miRNAs are found in close proximity to known genes, (Lagos-Quintana, Rauhut et 
al. 2001; Lim, Lau et al. 2005) which allows one to speculate that they are 
transcribed from single polycistronic transcription unit. So the conclusion drawn was 
that they can be transcribed as discrete as independent transcription unit or in a 
cluster by polycistronic transcription unit.  
MiRNA biogenesis 
miRNAs are transcribed as long primary transcripts by RNA polymerase II; 
subsequently trimmed into short hairpin intermediates called primary miRNAs and 
finally  processed into mature miRNAs.(Lee, Kim et al. 2004). The catalytic activity 
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of the enzymes responsible for first and second miRNA processing is 
compartmentalized into the nucleus and cytoplasm and is tightly regulated. (Figure 
1.6) 
Nuclear processing by Drosha  
RNase III endonuclease Drosha is a 160 kDa protein that is highly conserved in 
higher eukaryotes. (Filippov, Solovyev et al. 2000; Wu, Xu et al. 2000; Kristine R 
Fortin 2002) It contains two random RNAIII domains (RIIID) and a double stranded 
RNA binding domain (dsRBD) that are critical for its catalytic activity. Transcription 
of miRNA genes by RNA pol II yields primary transcripts (pri-miRNA) that are 
usually several kilobases long and contain a local hairpin structure. The pri-miRNA 
is first cleaved by RNase III endonuclease Drosha at sites near the base of stem loop, 
that releases ~60-70 nucleotide precursor miRNA. (Lee, Ahn et al. 2003) Drosha 
cleaves the pri-miRNA duplex with a staggered cut typical of RNase III 
endonucleases, leaving 2 nucleotide overhang at the 3’ end.(Lee, Ahn et al. 2003) 
The specificity with which Drosha recognizes and cleaves pri-miRNA has been 
under investigation. It was proposed on the basis of evidences from mutational 
studies that the tertiary structure of the pri miRNA is the factor that decides the 
specificity of Drosha. (CULLEN 2003; Lee, Ahn et al. 2003; Zeng, Yi et al. 2005)  
Nuclear export by exportin-5 
Following nuclear processing by Drosha, pre-miRNA is translocated to the 
cytoplasm through the nuclear pore complex embedded in the nuclear 
membrane.(Nakielny and Dreyfuss 1999) Export of the pre-miRNA is mediated by 
one of the nuclear transport receptors, exportin-5. (Rui Yi 2003; Lund, Güttinger et 
al. 2004) . Owing to the compartmentalization of the two processing events, the 
nuclear transport of pre-miRNA is a crucial step in miRNA biogenesis. (Kim 2004; 
Murchison and Hannon 2004) 
 
Cytoplasmic processing by Dicer 
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On reaching the cytoplasm, pre-miRNA is cleaved by cytoplasmic RNase III 
endonuclease Dicer, into ~ 22 nucleotide miRNA duplex. (Bernstein, Caudy et al. 
2001; Grishok, Pasquinelli et al. 2001; Hutvágner, McLachlan et al. 2001; Ketting 
2001; Knight and Bass 2001). Dicer is a highly conserved protein, found in all 
eukaryotes including Saccharomyces pombe, plants and animals. Apart from the two 
RIIID domains and dsRBD domain, Dicer contains long N terminal segment 
containing ‘dead box RNA helicase’ domain and PAZ domain.(Zhang, Kolb et al. 
2004) PAZ domain belongs to a group of highly conserved proteins called Argonaute 
preteins. Structural and biochemical studies of AGOI and AGOII in D.melanogaster 
revealed that PAZ domain binds to the 3’ protruding end of the small RNAs.(Song, 
Liu et al. 2003; Yan, Yan et al. 2003; Lingel, Simon et al. 2004) . Usually one strand 
of this short lived duplex disappears, whereas the other strand remains as mature 
miRNA. Mature miRNAs are incorporated into effector complexes that are known as 
microRNP (miRNA containing ribonucleoprotein complex), migronaute’ or 
microRISC (miRNA containing RNA inducing silencing complex). The strand that 
gets loaded in the microRISC complex is thought to be the one that has unstable base 
pairing at the 5’ end. (Khvorova, Reynolds et al. 2003; Schwarz, Hutvágner et al. 
2003). 
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Mechanism of miRNA mediated gene regulation 
miRNA can direct RISC to downregulate gene expression by either of the two post-
transcriptional mechanisms:  
1.) Translational repression 
2.) mRNA degradation/sequestration 
Mechanism of translational repression 
Once incorporated in the RISC complex, miRNA directs translational repression or 
target cleavage depending on degree of sequence  complimentarity with the 
target.(Hutvágner, McLachlan et al. 2001). In animals, there are several evidences 
suggesting that miRNAs recognize their target mRNA by limited base pairing 
between the 2-8 nucleotide seed region at the 5’end of the miRNA and the 3’ UTR of 
target mRNA.(Lewis, Shih et al. 2003; Farh, Grimson et al. 2005; Stark, Brennecke 
et al. 2005) The interaction between microRNPs and mRNA can have several 
consequences which can be direct or indirect. Direct effects include inhibition of 
translational initiation by preventing ribosome association with the internal ribosome 
entry site (IRES) on the target mRNA or inhibition post translation. Post 
translational repression includes premature ribosome drop off, stalled or slowed 
down elongation, and/or co-translational protein degradation; the repressed mRNA 
seems to be present in polyribosomes.(Nilsen 2007) (Figure 1.7) 
           Mechanism of mRNA degradation/sequestration 
Perfect sequence complimentarity between the seed region of miRNA and the 3’UTR 
of target sequence leads to the destabilization and subsequent degradation of the 
transcript. miRNAs achieve this by deadenylation and decapping of the target 
sequence, which results in degradation and increased turnover of the transcript. The 
site of miRNA directed target sequestration are thought to be the processing bodies 
(P bodies) also known as the GW bodies. The P bodies, which were originally 
described in budding yeasts, are known as the cytoplasmic foci rich in decapping , 
deadenylation enzymes and exonucleases required for mRNA degradation. 
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(THEOPHANY EYSTATHIOY 2003 October; Liu, Rivas et al. 2005; Eulalio, 
Behm-Ansmant et al. 2007) miRNA bound to the Argonaute protein in the RISC 
complex recognizes its target by complimentarity base pairing. The Argonaute 
protein interacts with the GW182 protein; miRNA-mRNA and argonaute protein 
complex is delivered to P bodies. In the P bodies, the mRNA is decapped and 
deadenylated, subsequently degraded or held in stasis i.e spatially isolated from the 
translational machinery since P bodies do not have ribosomes. (THEOPHANY 
EYSTATHIOY 2003 October; Liu, Valencia-Sanchez et al. 2005) In stasis, the P 
bodies are thought to act as repository for untranslated mRNAs and this has been 
experimentally proved in budding yeast as well as mammalian cells.(Brengues, 
Teixeira et al. 2005; Bhattacharyya, Habermacher et al. 2006) 
 
Figure 1.7 Mechanisms of miRNA mediated repression of gene expression. 
Mature single stranded miRNA loaded in a RISC complex targets and represses the 
translation of mRNA in more than one way, either directly or indirectly. In direct 
interaction, miRNA inhibits the initiation of translation by blocking the entry of 
ribosomes into the internal ribosomal entry site(IRES). Post translational initiation, 
miRNA can cause premature ribosome drop off , slowed or stalled elongation or co-
translational protein degradation. In indirect effects, miRNA targets the mRNA to P-
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bodies where they might undergo deadenylation and decapping by the enzymes 
present in the P-bodies and hence degraded or they might simply be sequestered from 
the translational machinery of the cell. In the later case, which is also called ‘stasis’ 
the P-bodies act as repository for all those mRNA that indirectly targeted by miRNA. 
(adapted and modified from Timothy Nilsen, 2007) 
MiRNA signatures in cancer 
Cancer is a complex genetic disease that involves aberrant expression pattern of 
coding as well as non-coding genes. Earlier it was thought that only the protein 
coding genes and their altered expression are involved in the pathogenesis of cancer 
but with the discovery of miRNAs, the understanding of cancer mechanisms and 
genomic complexity of cancer cell has completely changed. miRNAs have been 
proposed to contribute to oncogenesis either as tumor suppressors (eg- miR-15a and 
miR-16-1)  or oncogenes ( eg- miR-155 or members og the miR-17-92 cluster). The 
genomic abnormalties influencing miRNA expression in cancer are the same as for 
the protein coding genes eg- chromosomal rearrangement, genomic amplification, 
deletion and polymorphisms in the target site of the mRNA.(Abelson, Kwan et al. 
2005; He, Jazdzewski et al. 2005) 
Oncogenesis and tumor suppression - dual role of miRNAs 
Majority of the miRNAs are located in regions of genomic instability that undergo 
amplification or deletion which is why they have a huge role to play in the regulation 
of all major cancer pathways. miRNAs lying in regions that undergo genomic 
amplification act as oncogenes  eg-miRNA 17-92 cluster; whereas the chromosomal 
regions that undergo deletion in cancer, act as tumor suppressors eg- miRNAs 15s-
miR-16-1 cluster. O’Donnels in his work on cell model system showed that, human 
B-cell line P493-6, which overexpresses c-MYC, shows tumor suppressor activity 
through miRNA 17-92 cluster, which targets E2F1 and hence inhibits c-MYC 
regulated cell proliferation.(O'Donnell, Wentzel et al. 2005) The same cluster of 
miRNA when undergo amplification in the genome, act as oncogene by cooperating 
with c-MYC and promoting cell proliferation and blocking apoptosis. Hence it can 
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by concluded that miRNAs can participate in distinct cancer pathways with either the 
role of oncogene  or tumor suppressor depending on the cell type and expression 
pattern. Apart from their dual role, miRNAs can also act by targeting more than one 
mRNAs at the same time and have varied response .For eg-miRNA 15a and miRNA-
16-1 target the anti-apoptotic Bcl-2 in leukemia cells , however in 293 fetal kidney 
cells, where they are expressed, they don’t show any such response.(Calin, Liu et al. 
2004). The loss of miRNA 15a and miRNA 16-1, leads to the over-expression of 
Bcl-2 and consequently B-cell malignancies. In a different tissue, the over-
expression of miRNA 15a and miRNA 16-1 causes the loss of activity of a tumor 
suppressor that is critical to check cell proliferation and promote apoptosis in 
malignant cells. There are different mechanisms that can lead to aberrant miRNA 
expression in a cancerous cell- 
 
1.) Location of miRNA in cancer associated genomic regions 
More than 50% of known miRNAs are found in genomic regions that are prone to 
alteration in cancer cells.(Calin, Sevignani et al. 2004). Such regions include 
minimal regions of LOH (loss of heterozygosity), which are thought to harbor tumor 
suppressors genes, minimal regions of amplification, which mostly harbor 
oncogenes, common breakpoint region in or near possible oncogenes or tumor 
suppressor genes and fragile sites. 
 
2.) Epigenetic regulation of miRNA expression 
DNA hypomethylation, CpG island hypermethylation and histone modification 
losses represent epigenetic markers of malignant transformation and have been 
known to be one of the mechanisms involved in miRNA abnormal expression in 
cancer.((Fraga and Esteller 2005) 
 
3.) Abnormalities in miRNA processing genes and proteins 
Alterations in the proteins machinery that is involved in miRNA biogenesis, has 
dramatic effects on the miRNA expression. Failure of Drosha processing step or 
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Dicer mutation, could explain the downregulation of miRNA observed in primary 
tumors.(J. Michael Thomson1 2006)  
 
MiRNAs  in colorectal cancer 
Dysregulation of miRNA targeting tumor suppressors and oncogenes, have been 
reported in carcinogenesis of colorectal cancer. Two approaches are applied today to 
investigate the connection between miRNAs and CRC: functional and profiling 
studies. Many proteins involved in key signaling pathways of CRC, such as members 
of the Wnt/β-catenin and phosphatidylinositol-3-kinase (PI-3-K) pathways, KRAS, 
p53, extracellular matrix regulators as well as epithelial-mesenchymal transition 
(EMT) transcription factors (Fearon and Vogelstein 1990) are altered by miRNA in 
CRC (Figure 1.8). Study of these miRNAs  crucial for better understanding CRC 
pathogenesis with an aim to eventually identify novel therapeutic targets. Expression 
profiling of miRNAs have shown to have same potential for identification of 
biomarkers as profiling of their mRNA or protein counterparts. Together these 
studies help to determine the clinical prognosis of the disease along with 
identification of therapeutic targets. 
Few pathways that are prominent in CRC and provide evidence of involvement of 
miRNAs, are detailed below- 
MiRNA altering regulation of Wnt/β-catenin pathway in CRC  
The Wnt/β-catenin pathway plays a central role in an early colorectal tumor 
development. Inactivation of the adenomatous polyposis coli (APC) gene is a major 
initiating event in colorectal carcinogenesis occurring in more than 60% of colorectal 
adenomas and carcinoma. (Fearon and Vogelstein 1990). According to a recent study 
by Nagel et al.(Nagel, le Sage et al. 2008), miRNAs represent a novel mechanism for 
APC regulation in CRC. miR-135a and  miR-135b  decrease translation of the APC 
transcript in vitro. miR-135a and miR-135b were also found to be up-regulated in 
vivo in colorectal adenomas and carcinomas and correlated with low APC levels. 
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(Nagel, le Sage et al. 2008). These observations suggest that alteration in the miR-
135 family can be one of the early events in CRC's molecular pathogenesis. 
MiRNA regulating EGFR signaling (KRAS and phosphatidylinositol-3-kinase 
pathways) 
The epidermal growth factor receptor (EGFR) pathway contribute to promotion and 
progression of several solid tumors including colonic tumor. Stimulation of the 
EGFR and KRAS signaling lead to the activation of numerous signal transduction 
molecules initiating a cascade of downstream effectors that mediate tumor growth, 
survival, angiogenesis and metastasis. (Ciardiello and Tortora 2008)  KRAS 
oncogene has been reported to be a direct target of  the let-7 miRNA 
family.(Johnson, Grosshans et al. 2005). Another miRNA associated with KRAS 
regulation in CRC is miR-143.(Chen, Guo et al. 2009). Inhibition of KRAS 
expression by  miR-143 blocked constitutive phosphorylation of MAPK.(Chen, Guo 
et al. 2009). Another central signaling pathway downstream from EGFR and 
important in CRC development is the phosphatidylinositol-3-kinase (PI-3K) 
pathway. The p85β regulatory subunit involved in stabilizing and propagating the PI-
3K signal was mechanistically proven to be a direct target of miR-126. Furthermore, 
this p85β reduction mediated by miR-126 was accompanied by a substantial 
reduction in phosphorylated  AKT levels in the cancer cells, suggesting an 
impairment in PI-3K signaling. Another important regulatory component of the PI-
3K pathway, the tumor suppressor gene PTEN, is strongly repressed by miR-
21.(Meng F 2007 Aug) miR-21 is the miRNA most frequently up-regulated in 
CRC.(Slaby O 2007; Schetter, Leung et al. 2008; Krichevsky and Gabriely 2009) It 
appears that suppression of PTEN controlled by miR-21 is associated with 
augmentation of PI-3K signaling and progression of CRC. 
       MiRNAs regulating p53 pathway 
       Tumor suppressor gene p53 is mutated in about 50-75% of all CRCs and many other 
human tumors. (Hussain, Amstad et al. 2000) It has been speculated that p53-
mediated control of miRNA expression could allow it to indirectly repress target 
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gene expression at the post-transcriptional level. Recently, several groups have 
unraveled important aspects of connection between p53 and the miRNA 
network.(Hermeking 2007). The miRNA 34a-c family was found to be direct 
transcriptional targets of p53 and their targets regulate cell-cycle progression , 
cellular proliferation, apoptosis, DNA repair and angiogenesis. (Chang, Wentzel et 
al. 2007). Among the downregulated targets of the miR-34 family were well-
characterized p53 targets like CDK4/6, cyclin E2, E2F5, BIRC3 and Bcl-
2.Epigenetic silencing was found to be the mechanism of downregulation of miRNA 
34a-c in several CRC tumors. (Lodygin, Tarasov et al. 2008)  Hence, miRNA 34 a-c 
was identified as a tumor suppressor that is downregulated by epigenetic silencing in 
CRC, whereas in a normal cell it is associated with the p53 network. 
       MiRNAs in extracellular matrix breakdown and epithelial-mesenchymal transition 
       Epithelial mesenchymal transition (EMT) is the conversion of an epithelial cell into a 
mesenchymal cell. ECM remodeling is one of the processes in tumor growth, 
survival, invasiveness, and metastasizing. The key enzymes involved in ECM 
breakdown are the urokinase plasminogen activator (uPA) cascade and the matrix 
metalloproteinases (MMPs). (Takayama, Miyanishi et al. 2006)  Morphologically, 
EMT is characterized by a decrease of E-cadherin, loss of cell adhesion, and 
increased cell motility leading to promotion of metastatic behavior of cancer cells 
(including CRC ). (Asangani, Rasheed et al. 2007). The functional links to EMT 
comes from members of the miR-200 family (miR-200a, miR-200b, miR-200c, miR-
141 and miR-429). 
     MiRNAs regulating other signaling pathways in CRC  
miR-145 has been proposed as a tumor suppressor and is known to target the 3' UTR 
of insulin receptor substrate-1 (IRS-1) which dramatically inhibits the growth of 
colon cancer cells. (La Rocca, Badin et al. 2009) More recently, IGF-IR was proven 
to be another direct target of miR-145. (Gregersen, Jacobsen et al. 2010) 
Cyclooxyygenase-2 (COX-2) strongly contributes to the growth and invasiveness in 
CRC. miRNA 101 was found target COX-2 directly and cause translational 
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repression, hence playing the role of a tumor suppressor miRNA. (Strillacci, Griffoni 
et al. 2009) 
 
Figure 1.8 Aberrant miRNA expression affecting key pathways in colon 
carcinogenesis. Several miRNAs are involved in various stages of colon 
carcinogenesis. Inactivation of the APC gene of the Wnt/β catenin signaling pathway 
by miRNA 135 which is up-regulated in most CRC cases, leads to the stabilization 
and constitutive activation of β-catenin. This leads to transcription of genes 
promoting cell proliferation. Similarly, down-regulation of miRNA 145, which 
directly targets c-MYC increases cell proliferation. miRNA 143 and miRNA 126, 
which are down-regulated in CRC target KRAS and p85β subunit of P-I-3 kinase 
AKT pathway which leads to increased cell proliferation and survival. miRNA 
21,up-regulated in majority of CRC cases directly targets tumor suppressor PTEN. 
miRNA 34 a-c are p53 regulated miRNAs that target several of downstream p53 
targets eg-  CDK4/6, cyclin E2, E2F5, BIRC3 and Bcl-2. miRNA21 also targets 
RECK amd TIMP3 which are inhibitors of invasion and malignancy . Members of 
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miRNA 200 are negatively regulated by transcriptional activator ZEB3 which 
induces metastasis in CRC cells. 
MiRNAs as mediators of inflammation in colon cancer  
Specific miRNAs can be regulated by inflammatory stimuli and alternately certain 
miRNAs can act as mediators of inflammatory stimuli. Expression profiling reveal 
that lipopolysaccharide (LPS) induced inflammation causes altered expression of 
several miRNAs.(Taganov, Boldin et al. 2006; Sterghios A Moschos 2007). Studies 
showed that treatment with either of the pro-inflammatory cytokines, IL1b or TNFα 
stimulated the expression of miR-146a. (Schetter, Heegaard et al. 2010)The promoter 
region for miR-146a was found to contain NFκB binding sites, indicating that NFκB 
was probably responsible for driving the expression of miR-146a. (Taganov, Boldin 
et al. 2006). Lung inflammation due to allergic reactions showed increased miR-21 
expression.(Lu, Munitz et al. 2009). Rheumatoid arthritis which is a chronic 
inflammatory autoimmune condition affecting joints and tissues showed elevated 
levels of miR-146a.(Nakasa, Miyaki et al. 2008) Similarly, active inflammation in 
ulcerative colitis leads to increased expression of several miRNAs, including miR-
21.(Wu, Zikusoka et al. 2008). It is now thought that miRNA act as mediators in 
inflammation associated carcinogenesis such as colon cancer. It was seen that IL6, a 
pro-inflammatory cytokine, can induce the expression of miRNA-21 in a STAT3 
dependent manner. (Lu, Munitz et al. 2009) miRNA-155 stimulated in 
proinflammatory conditions, can target suppressor of cytokines 1 leading to the 
induction of NOS2.(Wang, Zhao et al. 2009). 
           Distal and proximal colon gives rise to different colonic tumors 
            In the last two decades, histological assessment of tumors, molecular evidences from 
population based and clinical studies in addition to tumor behavior studies in 
preclinical models have presented a case supporting the idea of existence of distal 
and proximal colonic tumor as separate diseases. (Iacopetta 2002; Li and Lai 2009). 
           Differences in physiology, embryology, molecular features like gene expression 
pattern etc exist between the normal right and left colon that are responsible for the 
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differences seen in the tumors appearing along the length of the colon. For example, 
the proximal colon originates from the embryonic midgut and is perfused by the 
superior mesenteric artery, whereas the distal colon derives from the hindgut and is 
served by the inferior mesenteric artery. The capillary network surrounding the 
proximal colon is multilayered, whereas that of the distal colon is single layered, 
possibly relating to the greater water absorption and electrolyte transport capacity of 
the former. (Araki, Furuya et al. 1996; Skinner and O'Brien 1996). The different 
absorptive nature of right and left colon might be duw to the differences in the 
average crypt length which is greater in case of distal than proximal.(Arai T 1989)  
(Table 1.1) 
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                      Table 1.1- Differences in right sided (proximal) and left sided (distal) colon. 
 
Features 
 
Proximal/ right sided colon 
 
Distal/left sided colon 
 
Anatomical 
location 
 
 
 
Embryologica
l origin 
 
Blood supply 
 
 
 
 
Function 
 
 
 
 
Average crypt 
length 
 
Location of 
stem cells and  
Direction of 
migration of 
colonocyte 
 
 
Type of cells 
in the crypt 
 
 
 
Morphology 
of tumors 
 
 
 
Molecular 
 
Right of splenic flexure 
consisting of caecum, ascending 
colon and transverse colon 
 
 
Midgut 
 
 
Branches from superior 
mesenteric artery 
Capillary network is multi-
layered 
 
Short chain fatty acid and 
ethanol fermentation 
 
 
 
Lesser compared to distal  colon 
 
 
Stem cells are located in mid 
crypt, colonocyte migration is 
bidirectional i.e, up towards the 
luminal surface and down 
towards the crypt base 
 
 
Lower one third has 
predominantly mucous cells and 
upper one third has columnar 
cells. 
 
Sessile serrated adenomas, 
hyperplastic polyps with low 
grade dysplasia 
 
 
Microsatellite instability 
 
Left of splenic flexure 
consisting of descending colon 
and sigmoid colon 
 
 
Hindgut 
 
 
Branches from inferior 
mesenteric artery 
Capillary network is single 
layered 
 
Protein fermentation, neutral 
muco-polysaccharide 
breakdown 
 
 
Greater compared to proximal 
colon 
 
Stem cells are located at crypt 
base and colonocyte migration 
is upwards towards luminal 
surface. 
 
 
 
Small number of mucous cells 
at the base, highest proportion 
of goblet cells. 
 
 
Traditional serrated adenomas, 
mostly pedunculated or 
villiform in appearance with 
high grade dysplasia 
 
Chromosomal instability 
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pathway for  
carcinogenesis 
 
 
 
 
 
 
 
 
 
Gene 
expression 
pattern 
 
 
 
 
 
 
 
 
 
 
 
Tumor 
behavior in 
response to    
to exogenous 
agents 
 
pathway, in which the DNA 
repair enzymes are silenced by 
promoter methylation, causing 
mutations in microsatellite 
regions of genes involved in cell 
proliferation, apoptosis.etc. 
BRAF mutation and high level 
of CpG island methylation 
leading to inactivation of MLH1 
and MGMT, result in high and 
low level MSI respectively 
 
Genes overexpressed include- 
phospho-  sulfotransferases, 
genes associated with ions, 
electrolyte, heterocyclic 
compounds, polycyclic 
hydrocarbons and steroids 
absorption e.g-cytochrome P450 
family genes, glutathione S-
transferase Z1, 3-β-
hydroxysteroid dehydrogenase1 
, hydroxysteroid(17β) 
dehydrogenase. 
 
Azoxymethane –less tumor 
High fat diet – no significant 
effect 
 
Fish oil diet- no significant 
effect 
 
High calcium diet- promotes 
growth of ACF/tumor 
Sulindac-induces new 
inflammatory lesions with 
malignant potential 
pathway ,in which there is 
allelic loss of chromosomes 
harbouring the APC, P53, K-
Ras genes. CpG island 
methylation in KRAS, leading 
to microsatellite stable (MSS) 
or low grade microsatellite 
instable (MSI-L) 
carcinogenesis. 
 
 
 
 
Genes overexpressed include-
phospholipase A2, genes 
associated with cell cycle 
control (cyclin D1,D2,G1, 
cyclin dependent kinase 2, 
PCNA), DNA replication, 
DNA damage repair, DNA 
adduct metabolism, TNFR2, 
NF-κB, IGR-IRα, IRα, and IRβ 
 
 
 
Azoxymethane – more tumor 
High fat diet – promotes 
growth of tumor 
 
Fish oil diet- retards growth of 
tumor 
 
High calcium diet-reduces 
growth of ACF 
Sulindac-regresses tumor 
growth 
              
Approximately 60% of CRC in high-incidence populations arise in the left colon 
(distal), whereas in low-incidence regions there is a predominance of right-sided 
(proximal) cases. (Haenszel W 1973). The incidence of proximal tumors in Western 
countries has steadily increased in the past decade while that of distal tumors has 
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shown a corresponding decrease.(Rhodes, Holmes et al. 1977).(Gervaz, Bucher et al. 
2004; Fenoglio, Castagna et al. 2010). The cases have been more common at an 
advanced age and in female gender of the population. (Okamoto, Stiratori et al. 
2002). Taken together, the geographic location, age and gender influences on CRC 
subsite distribution, in concert with the observations on proximal shift and migrant 
studies, suggests the existence of two broadly different mechanisms of CRC.  
 
Biological heterogeneity in colonic tumors depending on their spatial origin 
Morphologically and histologically colonic tumors exhibit different features. The 
adenomatous polyps differ in the degree of epithelial dyplasia, whereas hyperplastic 
polyps have serrated appearance without dysplasia. The mixed polyps are the ones 
that display both dysplasia as well as serrated appearance. Tumors could appear as 
sessile, pedunculated, polypoid, villous as well as flat lesions. These features allude 
to the possibility that the origin and biology of tumors differ. (Warnecke, Engel et al. 
2009)  Serrated neoplasia’s (SNs) with the hyperplastic pattern are located 
predominantly in the proximal colon and have superficial appearance, whereas SNs 
with the adenomatous pattern were observed in the distal colon and have a protruding 
appearance. (Noffsinger 2008). It has been noticed that the distribution of polyps 
with high grade dysplasia is more predominant in the distal region than 
proximal.(Goldstone, Itzkowitz et al. 2011)  
            Behavioral heterogeneity in colonic tumor   
            The concept that distal and proximal tumors could respond differently to cancer 
preventive agents and growth modulators, has been explored in preclinical models. 
Some of these require cancer induction by a carcinogen, whereas some models are 
genetically manipulated to address the role of specific pathway in 
carcinogenesis.(Vignjevic, Fre et al. 2007; Raju 2008). It has been previously 
established that pre-neoplastic lesions (ACF) appearing in response to chemical 
carcinogens like AOM are different in distal colon compared to proximal.(Bird RP 
1989) It has been  reported that distally located ACF grow more rapidly in response 
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to multiple injections of azoxymethane compared to their proximal 
counterparts.(Raju and Bird 2003). The interpretation here could be that proximal 
colonic regions resist growth modulating environment and respond slowly or that the 
test agent may not be as readily available to proximal colonic tissue. For e.g; high fat 
tumor promoting diet promotes the growth of distally located tumors and it is less 
effective in proximal tumors.(Kim, Chung et al. 1998; Hambly, Saunders et al. 
2002). A high fish oil diet in a high risk preclinical model of colon carcinogenesis is 
more effective in retarding the growth of distal developing tumors. (Hong, Chapkin 
et al. 2001)  Similarly a high calcium diet retards the growth of ACF in distal colon 
and tumors whereas has an opposite effect on the ACF or tumors developing in the 
proximal region. (Li, Kramer et al. 1998; Pierre, Taché et al. 2003) Recently, it was 
observed that a non-inflammatory drug Sulindac is able to regress distal colonic 
tumor in azoxymethane injected mice, whereas in the proximal region it induces new 
inflammatory lesions which develop into adenocarcinomas in upto 18-25% of p53 or 
mismatch repair deficient mice.(Mladenova, Daniel et al. 2011).In Zucker obese 
model, distally located tumors exhibited a phenotype compatible to enhanced growth 
than the proximal tumors. TNFα signaling pathway, insulin and expression of IGF 
receptors were higher in the distal colonic tumors.(Jain and Bird 2010) The most 
notable finding was that the ERK1 and 2 were differently expressed. Elevated 
expression of TNFR2, NF-κB, IGR-IRα, IRα, and IRβ was seen in the distal tumor 
mass compared to proximal tumor. Distal tumor showed high levels of NF-κB, IKKβ 
and lower level of IκB-α, which suggests that the pathway leading to activation of 
NFκB and subsequent survival genes is more active in distal colonic tumor compared 
to proximal. The presence of elevated levels of insulin, IGF-1R and TNF-α in the 
distal colon could also act synergistically to provide superior survival conditions to 
developing preneoplastic lesions in distal colon compared to proximal colon. (Jain 
and Bird 2010) 
Molecular heterogeneity evident in profiling studies in clinical system 
The distinct clinico-pathological characteristics as well as differences seen in tumor 
behavior along the colonic axis, is also reflected in the pattern of gene expression. 
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Some of these differences are thought to be acquired embryonic and post natal 
development, whereas some are speculated to be the result of interaction with the 
environmental risk factors, aging, diet etc. Microarray profiling of human colonic 
tumor showed >1000 genes that were differentially expressed in distal versus 
proximal tumor, seventy percent of which were highly expressed in distal colon 
compared to proximal colon.(Joyce and Pintzas 2007). The genes found to be 
differentially expressed in distal and proximal tumor are known to be involved in 
many cellular processes which include cell cycle, proliferation, cell death, response 
to external stimuli, stress response, and DNA replication and damage repair. These 
are also implicated in key signaling pathways known to be involved in colon 
carcinogenesis eg-EGF. The genes found to be differentially expressed in distal and 
proximal tumor are known to be involved in many cellular processes which include 
cell cycle, proliferation, cell death, response to external stimuli, stress response, and 
DNA replication and damage repair. These are also implicated in key signaling 
pathways known to be involved in colon carcinogenesis eg- EGF, TGF-β, Wnt, Ras, 
insulin and integrin signaling.(Glebov, Rodriguez et al. 2003). 
miRNA profiling in distal and proximal colonic tumor: evidences from clinical 
studies 
In recent years miRNAs have been been used as diagnostic tool to differentiate 
between right (proximal) and left sided (distal) colonic tumors. A comparitive study 
between normal colonic tissue and colon tumor from distal and proximal regions, 
showed several unique miRNAs that were differentially expression for microsatellite 
instability positive (MSI+) colon tumors found mostly in the proximal .There were 
several miRNAs that were differentially expressed for KRAS2-mutated colon 
tumors, and 139 miRNAs were differentially expressed for TP53-mutated colon 
tumors mostly seen in the distal region of the colon. (Slattery, Wolff et al. 2011). 
miRNA profiling of colon cancer samples characterized by microsatellite 
stability(MSS) and samples characterized by microsatellite instability showed 
differential expression of several miRNAs. miRNA 17-92 family showed 
  
38 
 
upregulation in MSS colonic tumor which is predominantly found in distal colonic 
region. 
miRNA has been used as diagnostic tool and biomarker for prognosis and predicting 
clinical  outcomes in colon cancer. With evidences from clinical and preclinical 
models supporting the concept of proximal and distal colonic tumor as distinct 
diseases, there is need to get deeper insight into the regulation of gene expression in 
these two regions of the colon. miRNA have shown distinct expression pattern in 
these regions further strengthening the molecular evidences in this regard. However, 
they are very few evidences from animal model study that look into miRNA 
expression pattern in distal and proximal colon in control or altered physiological 
state.  
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CHAPTER 3 
DESIGN AND METHODOLOGY 
 
Animals 
Female Zucker obese fa/fa (Zk-Ob) and lean (Zk-Ln) rats (n=10/group), weighing 
approximately 300 and 80 Kg respectively ,were obtained from Charles River 
Laboratories (Montreal, QB, Canada) at 12 weeks of age. They were housed in 
standard plastic cages with woodchip bedding and stainless steel wire mesh lid in the 
Biology Animal facility, University of Windsor, under controlled environmental 
conditions (22° C temperature, 50% humidity, 12 hour light/dark photo-period). 
Animal care and all investigative procedures adhered to guidelines of the Office of 
Research Ethics and Animal care committee of University of Windsor (AUPP# 10-
19) and the Canadian Council of Animal Care. Body weights of the animals was 
monitored twice a week and finally at termination. 
Following one week of acclimatization, animals were terminated by CO2 
asphyxiation. After recording weight of the body, liver and kidney, blood was 
obtained in heparinized or EDTA vacutainer tubes (BD Vacutainer Systems, NJ from 
a cardiac puncture using a multiple sample Luer adapter). Organs collected were 
stored in liquid nitrogen and kept at -80°C for future studies. 
Blood analysis 
Blood samples were centrifuged for 10 min at 2000 rpm to separate plasma, which 
was then aliquoted. Samples were either stored for further analysis  at -80ºC, or sent 
to Animal Health Laboratories  (University of Guelph, Guelph, ON)  for biochemical 
analysis of inflammatory cytokines (Interleukins), adhesion molecules like inter 
cellular adhesion molecules (ICAM), chemokines, Monocyte Chemoattractant 
Protein (MCP) ( appendix A.1) 
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Colon preparation 
Colon from each animal was removed, flushed with cold phosphate buffer saline and 
placed on a cold plate set at 4°C. A longitudinal cut was made from the rectal to the 
ceacal end. Mucosa from the colon was scraped separately from distal and proximal 
region of the colon and snap from in liquid nitrogen as well as RNA later (Sigma) for 
biochemical and molecular analysis. 
Total RNA isolation 
50-100 mg of frozen tissue was used to isolate total RNA using miRNeasy Mini Kit 
(Qiagen). The miRNeasy Mini Kit combines phenol /guanidine based lysis of 
samples and silica-membrane based purification of total RNA. Tissue samples were 
homogenized in QIAzol Lysis Reagent which is a monophasic solution of phenol and 
guanidine thiocyanate similar to TRIazol, which facilitates lysis of tissues, inhibits 
RNases, and removes most of the cellular DNA and proteins from the lysate by 
organic extraction. After addition of chloroform, the homogenate was separated into 
aqueous and organic phases by centrifugation. RNA was partitioned to the upper, 
aqueous phase, while DNA was partitioned to the interphase and proteins to the 
lower, organic phase or the interphase. The upper, aqueous phase was extracted, and 
ethanol (50%) was added to provide appropriate binding conditions for all RNA 
molecules from 18 nucleotides (nucleotide) upwards. The sample was then applied to 
the RNeasy Mini spin column, where the total RNA binds to the membrane and 
phenol and other contaminants were efficiently washed away. High-quality RNA was 
then eluted in RNase-free water. 
MiRNA isolation 
The flow through from the above step (using RNeasy Mini spin column), was mixed 
with 0.65 volumes (450µl) of 100% ethanol and vortexed. This sample was loaded 
into RNeasy MinElute spin column which was placed in 2ml collection tube. The 
samples were centrifuged for 1 minute at approximately 8000 x g (10,000 rpm) at 
room temperature (15-25°C). Flow through was discarded. Column was washed 
twice with 700µl of RWT buffer (wash buffer containing guanidine thiocyanate). 
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Column was finally washed with 80% ethanol. miRNA was eluted in 30µl of  RNase 
free water. 
Spectrophotometric quantification of miRNA-enriched fractions 
MiRNA enriched fractions prepared is assumed to contain many types of small RNA, 
including miRNA, snoRNA, and piRNA, as well as tRNA and a significant 
proportion of the 5S and 5.8S rRNA. Larger species, including tRNA, dominate the 
OD measurement of these fractions and also gel staining or assays which use RNA-
binding dyes. For this reason, it is not possible to quantify miRNA using OD 
measurements. Hence to quantify miRNA, qRT PCR was performed using miScript 
System (Qiagen). 
MiRNA to cDNA (Reverse-transcription step) 
10-20 ng of  miRNA enriched fraction of total RNA was converted to cDNA using 
RT2 mi RNA first strand kit (Qiagen) and primer specific probes. miScript Reverse 
Transcriptase Mix is an optimized blend of enzymes comprising of a poly (A) 
polymerase and  Reverse Transcriptase. The buffer system enables maximum activity 
of both enzymes besides containing  Mg2+, dNTPs ,oligo-dT primers, and random 
primers. Unlike mRNAs, miRNAs are not polyadenylated in nature.During the 
reverse-transcription step, miRNAs are polyadenylated by poly (A) polymerase. 
Reverse transcriptase converts RNA (including precursor miRNA, mature miRNA, 
other small noncoding RNA, and mRNA) to cDNA using oligo-dT and random 
primers. Polyadenylation and reverse transcription are performed in parallel in the 
same tube. The oligo-dT primers have a universal tag sequence on the 5' end. This 
universal tag allows amplification in the real-time PCR step. 
For each 10µl reaction, the components (Appendix B.1) were added to a regular pcr 
tube, mixed and stored in ice. The reaction was incubated at 37°C for 60 minutes and 
then for 5 minutes at 95°C to inactivate Reverse Transcriptase. 
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Real Time Quantification of miRNA 
MiRNA abundance was quantified using conventional two step quantitative reverse 
transcriptase real time PCR (q PCR) using miScript housekeeping primer assay for 
small nuclear RNA (RNU6 and 4.5s_V1). Template cDNA was characterized by qRT 
PCR using RT² SYBR Green/ROX qPCR Master Mix on the 7500 FAST Real-Time 
PCR System (Applied Biosystems). miRNAs were amplified using the miScript 
Universal Primer (Qiagen) , which primes from the universal tag sequence, together 
with the miScript Primer Assay for housekeeping small nuclear RNA. 
Reaction setup for real-time PCR based quantification of miRNA (Appendix B.2) 
For 20µl reaction volume, the components are added to a PCR tube, mixed 
thoroughly and kept in ice. 
Cycling conditions for real-time PCR for miRNA quantification – (Appendix B.3) 
Manual CT threshold value was adjusted to 0.02, again as per instrument 
specifications. Fold change in gene expression was calculated using the ∆∆ Ct 
method and analyzed with Sequence Detection System software (SDS version 2.0.5 
Applied Biosystems).  
MiRNA Rat Cancer PCR Array  
The differential expression of miRNA in colonic mucosa tissue was profiled using 
RT2 miRNA PCR Array system (SAbioscience / Qiagen). The universal primer in 
every assay of the RT2 mi RNA PCR Arrays is specific for the unique sequence 
incorporated into the cDNA by the universal RT primer in the RT2 mi RNA First 
Strand Kit. 
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Step 1- cDNA First Strand synthesis (Appendix B.4) 
The contents were mixed, followed by brief centrifugation. The samples were then 
incubated at 37°C for 2 hours; and then heated at 95°C for 5 minutes to degrade the 
RNA and deactivate the Reverse Transcriptase. The samples were then chilled on ice 
and 90µl of RNase free water was added to each 10 µl reaction volume.  
Step 2- Real Time PCR 
The 96 well RT2 miRNA cancer PCR array (SAbiosciences /Qiagen) was used for 
screening cancer miRNA coding genes from distal and proximal mucosa samples 
obtained from Zk-Ob and Zk -Ln rats.  
The components for were added to a 15 ml tube and mixed thoroughly with a pipette 
as per the manufacturer’s protocol. (Appendix B.5) 
25µl of the cocktail was added to each well of the 96 well Rat Cancer RT2 miRNA 
PCR Arrays (stored at -20°C). The array profiles the expression of 88 miRNA 
sequences (annotated by the Sanger miRBase Release 14.) which are implicated in 
cancer and related pathways directly or indirectly. Cycling conditions for real time 
PCR for the array experiment (Appendix B.6). 
The 10-minute step at 95°C was required to activate the HotStart DNA polymerase. 
SYBR Green fluorescence was detected and recorded from each well at the annealing 
step for each cycle. The threshold cycle CT was calculated using the instrument 
software, i.e Sequence Detection System software (SDS ver 2.0.5) Applied 
Biosytems. To define the Baseline, the Linear View of the amplification plots were 
used and the instrument was set to use the readings from cycle number three (3) to 
cycle number fifteen (15).Other amplification kinetics were measured on Applied 
Biosystems 7500 FAST sequence detector and analysed with Sequence Detection 
System software (SDS ver 2.0.5) Applied Biosytems. Data was analysed using ∆∆Ct 
method. 
MiRNA Sequence Specific Assays contained within each RT2 mi RNA PCR Array 
include one universal primer and one gene-specific primer for each mi RNA 
  
44 
 
sequence. Details of array layout (Appendix B.7) Controls used in the array are a 
panel of housekeeping Assay consisting of small nuclear RNA housekeeping assay 
panel which include Rnu6, U87, 4.5S_V1 and Y1. Duplicate Reverse Transcription 
Control (RTC) in the rray tests the efficiency of first strand  reaction with a primer 
set miRNA called External RNA Control (ERC) detecting the cDNA template 
synthesized. Positive PCR Control (PPC) tests the efficiency of the polymerase chain 
reaction itself using a pre-dispensed artificial DNA sequence and the primer set that 
detects it. 
Statistical Analysis 
DataAssistTM v3.0 Software (Applied Biosystems) was used as analysis tool for 
sample comparison using relative comparative CT (∆∆Ct ) method (Livak and 
Scmittgen, 2008) . It provides relative quantification analysis of gene expression 
through combination of statistical analysis by performing t-test for biological group. 
For graphical representation, relative quantification (RQ plot) was plotted that 
displays RQ (fold change) versus target assay. The cluster analysis and heat map was 
created using the DataAssistTM software v3.0 that graphically displays results of 
unsupervised hierarchical clustering. Distance between samples and assays were 
calculated for hierarchical clustering based on the ∆CT values using Pearson’s 
Correlation application of the DataAssist software. 
Target Prediction by bioinformatics analysis  
Several algorithms were used to predict potential targets of miRNA, such as 
miRanda (http://miRNA.sanger.ac.uk/targets/v4/), PicTar (http://pictar.bio.nyu.edu/), 
and TargetScan 3.1 (http://www.targetscan.org/). Potential target sequences were 
pooled for both rat and human mRNA and only those targets were considered that 
were conserved between the two species. Finally, the predicted targets were aligned 
against published  Affymetrix gene expression profile from rat distal and proximal 
colonic tissue.(Su, Bush et al. 2007).  
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Chapter 4 
ANALYSIS OF RESULTS 
 
Body weight, liver weight, kidney weight 
The average body weight of Zk-Ob (fa/fa) rats was 315gm. The average liver and 
kidney weight was 19.286 gm and 4.536 gm respectively. The average body weight 
of Zk-Ln(Fa/fa) rats was 86gm.The average liver and kidney weight was 10.77 gm 
and 3.87 gm respectively.  
Blood parameters 
A multiplex assay using antibody bead array technology (Appendix A.1) was 
used to assess the levels of specific cytokines and markers  associated with 
obesity and inflammation eg- ICAM-1, E-selectin, IL-1α, IL-6 and MCP-1. The 
markers that showing significantly higher levels in obese plasma compared to 
lean are as follows: 
 ICAM - obese 11569.8 pg/mol ±1582.64 versus lean 7810.48 pg/mol ±623.67 
 MCP - obese 389.06 pg/mol ±161.16 versus lean 167.55 pg/mol ± 19.95 
 E-Selectin - obese 94405.26 pg/mol ± 8415.09 versus lean 87697.38 pg/mol ± 
5588.32 
 IL-1α - obese 1996.3275 pg/mol ± 987.09 versus lean 1170.4025 pg/mol ± 284.98 
 IL-6 - obese 1875.13 pg/mol ± 887.62 versus lean 711.8825 pg/mol ± 90.37 
Results indicate a significant rise in levels of inflammatory cytokines (IL-1α, IL-6),   
chemokines (MCP) and cellular adhesion molecules (ICAM and E-selectin) in the 
blood plasma of Zk-Ob rats compared to their lean (control) counterparts. 
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Differential expression of miRNA in Zk-Ob and Zk-Ln liver 
This study was carried out to meet specific aim1 i.e establishing method of isolation and 
quantification of miRNA in rat tissue. Liver tissue was used to optimize the miRNA 
isolation since it is a large organ that provides sufficient start material to establish a 
methodology that was subsequently used to meet specific aim 2 and 3. Liver steotosis or 
abnormal accumulation of fats in the hepatic cell is a common symptom seen in obesity. 
It is a part of metabolic syndrome associated with obesity and is speculated to play an 
important role in inflammation associated metabolic disorders. Hence, liver along with 
colon can provide an insight into the role of obesity in regulation of miRNA expression. 
The miRNA expression pattern of Zk-Ob and Zk-Ln liver tissue, showed that 20 
miRNAs were significant up-regulated in Zk-Ob liver compared to Zk-Ln. These 
include miRNA 125a-5p, miRNA 132, mi RNA 137, miRNA 146 b, miRNA 15b, mi 
RNA 181a, mi RNA 181b, miRNA 183, miRNA 191, mi RNA 199a-3p, miRNA 
199a-5p, miRNA 200, miRNA 21, miRNA 218, mi RNA 223, mi RNA 23a, miRNA 
27a, miRNA 34a, miRNA 429 and miRNA 96. (Figure 4.1) There were few that 
showed more than 2 fold up-regulation but were not found to be statistically 
significant. Similarly, few miRNA were found to be almost two fold down-regulated 
in Zk-Ln, though not significant. Out of the 20 miRNAs that showed significant 
differential regulation in Zk-Ob liver compared to lean, 3 prominent ones, namely 
miRNA 21, miRNA 199-3p and miRNA -5p were picked for independent validation 
studies. In their individual validation studies, all three of them showed significant 
up-regulation in Zk-Ob liver compared to Zk-Ln liver in accordance with the array 
studies (Figure 4.2).  
The method of miRNA isolation and quantification was successfully established 
(specific aim1). Several miRNAs were found up-regulated in obese liver compared to 
lean, establishing the fact that obesity influences miRNA expression irrespective of 
genotype.(Table 4.1) Through validation studies, it was further confirmed that 
miRNA 21, miRNA 199-3p and miRNA 5p are up-regulated under obese conditions.  
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Figure 4.1 Differential expression of miRNAs in liver tissue of Zk-Ob versus Zk-
Ln. miRNA abundance in the samples was normalized using miRNA 4.5s_V1 as 
endogenous control. The abundance of each of the candidate miRNAs is represented 
as linear RQ or fold change of obese compared to lean ( reference sample ). P-values 
are calculated using student t-test application of DataAssist software v3. 
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Figure 4.2 Validation of selected miRNAs in independent sample set. miRNA 
was isolated from idependent set of liver tissue from Zk-Ob and Zk-Ln rats (n=3). 
Individual miRNA primer assays for miRNA 21, miRNA, 199-3p and miRNA 199-
5p were used to measure of miRNA abundance in obese versus lean liver tissue using 
q RT PCR. Here the individual miRNA abundance is plotted against fold change 
(RQ). Data was normalised using 4.5s_v1 as endogenous control and significance 
was calculated by student t-test(**p<0.05, **p<0.01, ***p<0.001 )  Panel (a)-
miRNA 21 shows approx.1.5 fold abundance in Zk-Ob liver compared to Zk-Ln;  
panel (b.) miRNA 199-3p shows 4 fold abundance in Zk-Ob liver compared to Zk-
Ln;  panel(c.) miRNA 199-5p shows 4 fold abundance in Zk-Ob liver compared to 
Zk-Ln.  
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Table 4.1-Significantly up-regulated miRNAs in Zk-Ob liver compared to Zk-Ln liver and their function/target 
miRNA 
 
Fold 
change 
Direction Adjusted 
P-value 
Cellular function/target Reference 
miRNA 
125a-5p 
6.32 up-
regulation 
   0.02 directly targets oncogene 
ERBB2 in gastric carcinoma 
cells, negatively regulates cell 
proliferation and metastasis, 
EGFR regulated tumor 
suppressor, regulates the 
inflammatory response, lipid 
uptake in 
monocytes/macrophages 
 
(Chen, Huang et al. 2009; 
Nishida, Mimori et al. 
2011; Guofu Wang 2009 
October) 
 
miRNA 132 
 
7.91 
 
up-
regulation 
 
  0.003 
targets tumor suppressor protein 
rein retinoblastoma (pRb) in 
panc nreatic cancer cells, thus 
increasing cecell proliferation, 
potentiates Cholinergic Anti-
Inflammatory Signaling by 
Targeting Acetylcholinesterase 
 
(Shaked, Meerson et al. 
2009; Park, Henry et al. 
2011) 
miRNA 137 40.77 up-
regulation 
 0.015 acts as a tumor suppressor in 
colon and is often silenced by 
promoter methylation, targets 
carboxyl terminal binding 
protein1 that acts as co-
repressor for many tumor 
suppressor genes, targets Cdc2 
expression, induces G1 cell 
(Liu, Lang et al. 2011; 
Zhang, Hao et al. 2011) 
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cycle arrest and inhibits 
invasion in CRC cells. 
 
miRNA 
146b 
7.82 up-
regulation 
 0.022 supresses NF-κB activity in 
breast cancer cells,expressed in 
response to rising inflammatory 
cytokine levels as part of 
negative feed back loop that 
restrains excessive senescence 
associated secretory phenotype. 
 
(Bhaumik, Scott et al. 
2008; Dipa Bhaumik1 
2009) 
miRNA 15b 6.82 up-
regulation 
 0.024 E2F (promotes cell 
proliferation) regulated which 
in turn regulates E2F activity, 
associated with increased cell 
proliferation and decreased 
apoptosis. 
 
(Satzger, Mattern et al. 
2010; Ofir, Hacohen et al. 
2011) 
miRNA  
181a 
7.92 up-
regulation 
0.037 induced by Wnt/β catenin 
signaling, including Wnt10 
over-expression. 
 
(Bioscience 2011) 
miRNA 
181b 
3.9398 up-
regulation 
0.013 expression promotes G1 to S 
transition, targets CBX7 and 
cell death associated genes eg- 
PCD4, BCl11etc 
 
(Gelsomina Mansueto 
2010 ) 
 
 
miRNA 183 12.32 up-
regulation 
0  0.009 functions as oncogene by 
targeting transcription factor 
EGR1,PTEN and promoting 
cell migration 
 
(Sarver, Li et al. 2010) 
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miRNA 191 3.97 up-
regulation 
0.014 oncogene that promotes cell 
proliferation and inhibits 
apoptosis in hepatocarcinoma, 
targets MDM4 
which down-regulates p53. 
 
(Elyakim, Sitbon et al. 
2010; Wynendaele, 
Böhnke et al. 2010) 
miRNA 199-
3P 
19.97 up-
regulation 
0.006 regulates cell proliferation and 
survival by targeting Caveolin-
2,targets mTOR and c-Met in 
human hepato-carcinoma cells 
(Fornari, Milazzo et al. 
2010; Shatseva, Lee et al. 
2011) 
miRNA 199-
5p 
15.77 up-
regulation 
0.008 targets hypoxia inducible 
factor-α in hepatocellular 
carcinoma, discoidin domain 
receptor-1 (DDR1) tyrosine 
kinase, involved in cell 
invasion-related signaling 
pathway is targeted by miRNA 
199-5p,targets HES which 
negatively regulates cell 
proliferation 
 
(Livia Garzia 2009; Qingli 
Shen1 2010; Wang, Song 
et al. 2011) 
miRNA 200c 12.74 up-
regulation 
0.009 suppresses E-Cadherin and 
other genes related with EMT 
transition, by targeting ZEB1 
and ZEB2 
(Howe, Cochrane et al. 
2011) 
miRNA 21 4.98 up-
regulation 
0.036 acts as oncogen by targeting 
tumor suppressor gene 
tropomyosin (TPM1), 
programmed cell death 
1(PCD4) and maspin, both 
implicated in metastasis and 
invasion,directly targets PTEN 
tumor suppressor, EGFR 
(Zhu, Wu et al. 0000; Hurt 
and Farrar 2007; Meng, 
Henson et al. 2007) 
9:227 (Seike, Goto et al. 
2009) 
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regulated anti apoptotic factor 
 
miRNA 218 8.09 up-
regulation  
0.036 targets EGFR  that regulates 
NF-κB activity and is 
associated with apoptotic 
response, tumor suppressor 
activity in lung squamous cell 
carcinoma, targets mTOR 
 
(Davidson, Larsen et al. 
2010; Gao, Zhang et al. 
2010; Uesugi, Kozaki et 
al. 2011) 
miRNA 223 
 
 
 
 
 
 
 
 
 
 
 
miRNA 23a 
 
 
 
 
 
 
miRNA 27a 
 
 
 
7.92 
 
 
 
 
 
 
 
 
 
 
 
3.95 
 
 
 
 
 
 
5.00 
 
 
 
up-
regulation 
 
 
 
 
 
 
 
 
 
 
up-
regulation 
 
 
 
 
 
up-
regulation 
 
 
0.03 
 
 
 
 
 
 
 
 
 
 
 
0.013 
 
 
 
 
 
 
0.035 
 
 
 
targets starthmin1(onco-protein) 
in hepatocarcinoma cells, 
promotes gastric cancer 
invasion and metastasis by 
targeting tumor suppressor 
EPB41L3, negatively correlated 
with oncogene c-myc, targets 
tumor suppressor FBW7, that 
targets oncoproteins like cyclin 
E, c-myc for degradation, 
induces expression of GLUT3 
 
acts as tumor supprerssor by 
promoting and antiapoptotic 
factor in hepatocellular 
carcinoma cells, downregulates 
interleukin -6 receptor 
 
 
oncogenic, targets ZBTB10 and 
Myt1 which cataylses 
phosphorylation of cdc2 to 
inhibit progression of cells from 
(Wong, Lung et al. 2008; 
Lu, Buchan et al. 2010; 
Xu, Sengupta et al. 2010; 
Li, Zhang et al. 2011; 
Zhao WY 2011 Feb) 
 
 
 
 
 
 
 
 
(Zhu, Liu et al. 2010) 
 
 
 
 
 
 
(Sudhakar Chintharlapalli 
2009, october 15) 
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miRNA 34a 
 
 
 
 
 
 
miRNA 429  
 
 
 
 
miRNA 96 
 
 
3.14 
 
 
 
 
 
 
32.08 
 
 
 
 
24.84 
 
 
up-
regulation 
 
 
 
 
 
up-
regulation 
 
 
 
up-
regulation 
 
 
0.042 
 
 
 
 
 
 
0.006 
 
 
 
 
0.006 
G2 to M phase 
 
p53 dependent  tumor 
suppressor, 
targets CDK4/6, E2F5, BcL2, 
SIRT1 (negative regulator of 
apoptosis under stress 
conditions) 
 
modulates expression of c-myc, 
playes important role in 
pathogenesis of gastric 
carcinoma 
 
targets KRAS, acts as tumor 
suppressor in pancreatic cancer 
 
 
 
(Munekazu Yamakuchi*† 
June 25, 2008) 
 
 
 
 
 
(Sun, Wang et al.) 
 
 
 
 
(Yu, Lu et al. 2010) 
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Differential expression of miRNA in distal and proximal colon of Zucker lean 
rat (control) 
This study was conducted to determine the miRNA expression profile in right and 
left sided colon using Zk-Ln rats as control. It was found that 9 out of the 88 
miRNAs on the array showed statistically significant fold increase (P< 0.05) in 
proximal colonic mucosa compared to distal. There were few miRNAs that showed 
down-regulation for eg- miRNA 221 and miRNA 222 showed 0.6223 and 0.2513 
down-regulation respectively. However, they did not show any statistically 
significance. miRNAs that showed significant up-regulation(P <0.05) in proximal 
colon mucosa compared to distal include miRNA-143, miRNA-152, mi-RNA 206, 
miRNA-218, miRNA- 223, miRNA 29b, miRNA-30c,miRNA-363, miRNA 335. 
(Figure 4.3) There were atleast 10 more miRNAs that showed more than 2 fold up-
regulation but they were all found to be statistically insignificant.  
Looking at the lean (control) group alone, it can be concluded that miRNA are 
differentially expressed in distal and proximal regions of the colon (specific 
aim2).(Table 4.2) The possibility of few or all of these miRNAs serving as 
biomarkers for specific colonic regions would depend on the consistency of their 
trend of expression under other physiological conditions. 
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Figure 4.3 Differential expression of miRNAs in Zk-Ln proximal colonic mucosa 
versus Zk-Ln distal colonic mucosa. miRNA abundance in the samples was 
normalized using miRNA 4.5s_V1 as endogenous control. The abundance of each of 
the candidate miRNAs is represented as linear RQ or fold change of Zk-Ln proximal 
colonic mucosa compared to Zk-Ln distal colonic mucosa (reference sample). P-
values are calculated using student t-test application of DataAssist software v3.0. 
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Table 4.2- Significantly up-regulated miRNAs in Zk-Ln proximal colon compared to Zk-Ln distal colon and their 
function/targets 
mi RNA Fold 
change 
Direction Adjusted
-P value 
Cellular function/target Reference 
miRNA 143 25.74 up-
regulation 
0.046 targets KRAS oncogene, 
operational in colon cancer, targets 
DNA methyl transferases3 in colon 
cancer 
(Ng, Tsang et al. 
2009; Gao, Zhang et 
al. 2011) 
miRNA 152 8.04 up-
regulation 
0.046 induces aberrant DNA methylation 
in Hepatitus B virus related 
Hepatocarcinoma by targeting 
DNA methyl transferaseI 
(Jinfeng Huang July 
2010) 
mi RNA 206 32.32 up-
regulation 
0.032 targets notch3 ,activates 
apoptosis,inhibits tumor cell 
migration 
(Song, Zhang et al. 
2009) 
miRNA 218 130.73 up-
regulation 
0.046 targets EGFR  that regulates NF-κB 
activity and is associated with 
apoptotic response, tumor 
suppressor activity in lung 
squamous cell carcinoma, targets 
mTOR 
(Davidson, Larsen et 
al. 2010; Gao, Zhang 
et al. 2010; Uesugi, 
Kozaki et al. 2011) 
miRNA 223 41.17 up-
regulation 
0.047 targets starthmin1(oncoprotein) in 
hepatocarcinoma cells, promotes 
gastric cancer invasion and 
metastasis by targeting tumor 
suppressor EPB41L3, negatively 
correlated with oncogene c-myc, 
(Wong, Lung et al. 
2008; Xu, Sengupta 
et al. 2010; Li, 
Zhang et al. 2011; 
Zhao WY 2011 Feb) 
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targets tumor suppressor FBW7, 
that targets oncoproteins like cyclin 
E, c-myc for degradation, induces 
GLUT4 expression 
miRNA 29b 10.12 up-
regulation 
0.047 induces global DNA 
hypomethylation by directly 
targeting DNMT1 
(Garzon, Liu et al. 
2009) 
miRNA 30c 16.28 up-
regulation 
0.032 associated with HER and RAC1 
signaling pathways in breast cancer 
(F Germán 
Rodríguez-González 
2011) 
miRNA 363 16.57 up-
regulation 
0.032 regulated by insulin growth factor 
receptor IGF-R, down-regulated in 
colon cancer. 
(Adhip  PN 
Majumdar1 April 
2010 ) 
miRNA 335 258.02 up-
regulation 
0.047 miRNA-335 acts as a metastasis 
suppressor in gastric cancer by 
targeting Bcl-w 
(Xu, Zhao et al. 
2011) 
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Differential expression of miRNA in distal and proximal colon of Zk-Ob rats 
under conditions of chronic inflammation 
The aim of this study was to identify the key miRNAs that are differentially 
expressed in proximal versus distal colon under obese conditions. It was found that 
15 out of the 88  miRNAs on the array, showed significant fold decrease (P<0.05) in 
proximal colon compared to distal colon. (Figure 4.4) Interestingly, most of the 
miRNAs were found to be down-regulated in proximal colon compared to distal. 
Among the miRNAs that were found to be significantly down-regulated, are miRNA 
125a-5p, miRNA 132, miRNA 133b, miRNA 181d, miRNA 183, miRNA199a-5p , 
miRNA 21, miRNA 223, miRNA301a, miRNA320, miRNA 34a, miRNA 378, 
miRNA 708, miRNA 7a and miRNA 92a. miRNA 223, that was found significantly 
up-regulated in lean proximal colon was found significantly down-regulated in 
proximal colon under conditions of obesity. miRNA 21, which is associated with 
inflammation was down-regulated in proximal colon of Zk-Ob rat as well. Most of 
the other miRNAs that were down-regulated in proximal colon compared to distal 
were not statistically significant. 
In this study, several observations were made regarding the role of obesity in 
regulation of miRNA expression. Firstly, obesity seems to have a profound on 
several miRNAs in the colon which shows that inflammation is a key factor 
involved. (Table 4.3) Secondly, miRNA 223 that was significantly up-regulated in 
proximal colon compared to distal in the control lean group, was significantly down-
regulated under obese conditions. Interestingly, this miRNA is also down-regulated 
in hepatocellular carcinoma, where it acts as tumor suppressor by directly targeting 
Stathmin1 oncogene. (Wong, Lung et al. 2008) Similar trend was observed in case of 
few others miRNAs also, however they were not significant.  
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Figure 4.4 Differential expression of miRNAs in Zk-Ob proximal colonic mucosa 
versus Zk-Ob distal colonic mucosa. miRNA abundance in the samples was 
normalized using miRNA 4.5s_V1 as endogenous control. The abundance of each of 
the candidate miRNAs is represented as linear RQ or fold change of Zk-Ob proximal 
colonic mucosa compared to Zk-Ob distal colonic mucosa (reference sample). P-
values are calculated using student t-test application of DataAssist software v3.0  
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Table 4.3- Significantly down-regulated miRNAs in Zk-Ob proximal colonic mucosa compared to Zk-Ob distal colonic 
mucosa  
miRNA  Fold 
regul
ation 
Direction P value Cellular function/target Reference 
miRNA-
125a-5p 
0.004 down-
regulation 
0.008 directly targets oncogene ERBB2 in gastric 
carcinoma cells, negatively regulates cell 
proliferation and metastasis, EGFR regulated 
tumor suppressor, regulates the inflammatory 
response, lipid uptake in 
monocytes/macrophages 
(Chen, Huang et al. 
2009; Nishida, 
Mimori et al. 2011; 
Guofu Wang 2009 
October) 
miRNA 132 0.009 down-
regulation 
0.023 targets tumor suppressor protein 
retinoblastoma (pRb) in pancreatic cancer 
cells, thus increasing cell proliferation, 
Potentiates Cholinergic Anti-Inflammatory 
Signaling by targeting acetylcholinesterase 
 
(Shaked, Meerson et 
al. 2009; Park, Henry 
et al. 2011) 
miRNA 
133b 
0.010 down-
regulation 
0.048 targets pro survival signals MCL-1 and 
BCL2L2 in lung cancer 
(Melissa Crawford 
August 2009 
) 
miRNA 
181d 
0.024
7 
down-
regulation 
0.049 targets tissue inhibitor of matrix 
metalloproteinase (TIM3) in 
hepatocarcinogensis, induced by β catenin 
signalling 
(Wang, Hsu et al. 
2010; Junfang Ji 
2011 January 18) 
miRNA 183 0.032 down- 0.013 functions as oncogene by targeting 
transcription factor EGR1 and promoting cell 
Sarver, L  i et al. 2010) 
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9 regulation migration 
miRNA 
199a-5p 
0.003
2 
down-
regulation 
0.008 targets hypoxia inducible factor-α in 
hepatocellular carcinoma, discoidin domain 
receptor-1 (DDR1) tyrosine kinase, involved 
in cell invasion-related signaling pathway is 
targeted by miRNA 199-5p 
(Qingli Shen1 2010) 
mi RNA 21 0.012 down-
regulation 
0.049 acts as oncogene by targeting tumor 
suppressor gene tropomyosin(TPM1), 
programmed cell death 1(PCD4) and maspin, 
both implicated in metastasis and 
invasion,directly targets PTEN tumor 
suppressor, EGFR regulated anti apoptotic 
factor 
(Zhu, Wu et al. 0000; 
Hurt and Farrar 2007; 
Meng F 2007 Aug; 
Seike, Goto et al. 
2009) 
mi RNA 
223 
0.008 down-
regulation 
0.024 targets starthmin1(oncoprotein) in 
hepatocarcinoma cells, promotes gastric 
cancer invasion and metastasis by targeting 
tumor suppressor EPB41L3, negatively 
correlated with oncogene c-myc, targets tumor 
suppressor FBW7, that targets oncoproteins 
like cyclin E, c-myc for degradation, induces 
GLUT4 expression 
 
(Wong, Lung et al. 
2008; Xu, Sengupta 
et al. 2010; Li, Zhang 
et al. 2011; Zhao WY 
2011 Feb) 
miRNA 301 0.005 down-
regulation 
0.012 oncogenic role in breast cancer,controls cell 
proliferation, clonogenicity, migration, 
invasion, tamoxifen resistance, tumor growth, 
and micro vessel density 
(Shi, Gerster et al. 
2011) 
miRNA 320 0.051 down-
regulation 
0.038 oncogenic role, cell proliferation, detected in 
highly proliferative coloin crypts in CRC 
(Schepeler, Reinert et 
al. 2008) 
miRNA 34a 0.019 down-
regulation 
0.008 p53 dependent  tumor suppressor, 
targets CDK4/6, E2F5, BcL2, SIRT1 (negative 
(Munekazu 
Yamakuchi*† June 
  
62 
 
regulator of apoptosis under stress conditions) 
 
25, 2008) 
miRNA 378 0.031 down-
regulation 
0.031 oncogenic, promotes cell survival, tumor 
growth, and angiogenesis by targeting SuFu 
and Fus-1 expression 
 
(Lee, Deng et al. 
2007) 
miRNA 708 0.004 down-
regulation 
0.009 tumor suppressor role, induces apoptosis and 
suppresses tumorigenicity in renal cancer cells 
 
(Saini, Yamamura et 
al. 2011) 
miRNA7a 0.039 down-
regulation 
0.035 inhibits proliferation of human prostate cancer 
cells in vitro and in vivo by targeting E2F2 
and CCND2 
 
(Dong, Meng et al. 
2010) 
miRNA 92a 0.032 down-
regulation 
0.037 biomarker for detection of leukemia, controls 
angiogenesis 
(Tanaka, Oikawa et 
al. 2009),(Angelika 
Bonauer 2009) 
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Differential expression of miRNA  in  Zk-Ob compared to Zk-Ln rat colon 
As part of specific aim 3, the purpose of this study was to find out if obesity alters 
the miRNA expression levels when compared to its lean control. Secondly to identify 
miRNAs those are affected by obesity independent of location on the colon. 
In the first part of this study, the differential expression of miRNA in the proximal 
colon of Zk-Ob compared to proximal colon of  Zk-Ln was studied. It was found that 
compared to Zk-Ln proximal colon, the Zk-Ob proximal colon showed down-
regulation of most the miRNAs, though majorities were not statistically significant. 
The miRNAs that were significantly down-regulated in Zk-Ob proximal colon 
compared to Zk-Ln proximal colon include miRNA132, miRNA 125a-5p, miRNA 
134,  miRNA 138, miRNA 15b, miRNA 16, miRNA 191, miRNA 195, miRNA 
199a-5p, miRNA 223, miRNA 27a, miRNA 29a, miRNA 301a, miRNA 30c, miRNA 
378, miRNA 429, miRNA 708, miRNA 7a and miRNA 92a. ( Figure 4.5)  Whereas, 
miRNA 181-b ( fold change =18.0851,p value=0.281) , miRNA 200c (fold 
change=3.5934, p value=0.8087) , miRNA 210 (fold change=2.233, p value=0.7937) 
and miRNA 222 (fold change=4.4617, Pvalue = 0.2822) were found to be up-
regulated in Zk-Ob proximal colon compared to lean proximal but none were 
statistically significant. Interestingly, miRNA 223 which acts as tumor suppressor in 
hepatocellular carcinoma was again found to be down-regulated in Zk-Ob proximal 
colon compared to Zk-Ln proximal. (Table 4.4) 
In the other part of the study, the differential expression of miRNA in distal colon of 
Zk-Ob versus distal colon of Zk -Ln rats was studied. Here, most of the miRNAs are 
up-regulated in Zk-Ob distal colon compared to Zk-Ln distal. The miRNAs that show 
significant up-regulation include- miRNA 142-5P, miRNA 146b, miRNA 150, 
miRNA 218, miRNA 223, miRNA 29b and miRNA 9. (Figure 4.6) All the other 
miRNAs that show up-regulation in Zk-Ln distal colon in comparison to Zk-Ln distal 
do not show statistical significance. Very few miRNA like miRNA let -7a, miRNA 
103, miRNA 29a , show down-regulation  but they are statistically insignificant. 
miRNA 223, shows significant up-regulation in distal region of Zk Ob rat compared 
to it lean counterpart.(Table 4.5) 
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Looking at the two study groups, it is clearly evident that obesity does alter miRNA 
expression levels when compared to control lean group. What is interesting to note 
here is that obesity also seems to have a region specific effect on the colon which 
reconfirms the fact that distal and proximal colon are distinct regions of the colon. 
miRNAs that are up-regulated in proximal region of obese colon compared to lean 
are down-regulated in distal region. For eg- miRNA 223 is up-regulated in Zk-Ob 
proximal colon compared to its lean counterpart. However it is significantly down-
regulated in distal colon of Zk Ob rats compared to distal colon of Zk-Ln. There are 
few other miRNAs eg- miRNA134, miRNA 199-5p and miRNA 708 that showed a 
similar trend but were not statistically significant. (not included in result) This 
reiterates the fact that proximal and distal colon indeed have distinct miRNA 
expression profile and  falls in place with the existing theory of colon having two 
biologically distinct parts called proximal(right) and distal(left) colon. Secondly, 
obesity plays a major role in regulating miRNA expression in region specific 
manner. 
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Figure 4.5 Differential expression of miRNAs in Zk-Ob proximal colonic mucosa 
versus Zk-Ln proximal colonic mucosa. miRNA abundance in the samples was 
normalized using miRNA 4.5s_V1 as endogenous control.The abundance of each of 
the candidate miRNAs is represented as linear RQ or fold change of Zk-Ob proximal 
colonic mucosa compared to Zk-Ln proximal colonic mucosa (reference sample). P-
values are calculated using student t-test application of DataAssist software v3.0  
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Table 4.4-Significantly down-regulated miRNAs in Zk-Ob proximal colon compared to Zk-Ln proximal colon and their 
function/targets 
mi RNA Fold 
change 
Direction Pvalue Cellular function/target Reference 
miRNA 132 0.043 down-
regulation 
0.0497 targets tumor suppressor protein rein 
retinoblastoma(pRb) in pancreatic 
cancer cells, thus increasing cell 
proliferation, potentiates cholinergic 
anti-inflammatory signaling by 
targeting acetylcholinesterase 
 
(Shaked, Meerson et 
al. 2009; Park, 
Henry et al. 2011) 
miRNA 
125a-5p 
0.008 down-
regulation 
0.024 directly targets oncogene ERBB2 in 
gastric carcinoma cells, negatively 
regulates cell proliferation and 
metastasis, EGFR regulated tumor 
suppressor, regulates inflammatory 
response and lipid uptake in 
macrophages/ monocytes 
 
(Chen, Huang et al. 
2009; Nishida, 
Mimori et al. 2011; 
Guofu Wang 2009 
October) 
miRNA 138 0.027 down-
regulation 
0.041 tumor suppressor, associated with 
over-expression of human telomerase 
reverse transcriptase protein in human 
anaplastic thyroid carcinoma cell 
lines. 
 
(Mitomo, Maesawa 
et al. 2008) 
miRNA 15b 0.043 down-
regulation 
0.042 oncogenic, correlated with tumor cell 
proliferation and apoptosis in 
malignant melanoma 
 
(Satzger, Mattern et 
al. 2010) 
miRNA 16 0.0137 down- 0.0433 tumor suppressor, inhibits the growth (Takeshita, 
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regulation of metastatic prostate tumors via 
down-regulation of multiple cell-cycle 
genes 
 
Patrawala et al. 
2009) 
miRNA 191 0.005 down-
regulation 
0.031 oncogene that promotes cell 
proliferation and inhibits apoptosis in 
hepatocarcinoma, targets MDM4 
which down-regulates p53 
 
(Elyakim, Sitbon et 
al. 2010; 
Wynendaele, 
Böhnke et al. 2010) 
miRNA 195 0.003 down-
regulation 
0.017 tumor suppressor promotes apoptosis 
and suppresses tumorigenicity of 
human colorectal cancer cells 
 
(Liu, Chen et al. 
2010) 
miRNA 
199-5p 
0.017 down-
regulation 
0.010 targets hypoxia inducible factor-α in 
hepatocellular carcinoma, discoidin 
domain receptor-1 (DDR1) tyrosine 
kinase, involved in cell invasion-
related signaling pathway is targeted 
by miRNA 199-5p, targets HES 
which negatively regulates cell 
proliferation 
 
(Livia Garzia 2009; 
Qingli Shen1 2010; 
Wang, Song et al. 
2011) 
miRNA 223 0.022 down-
regulation 
0.022 targets starthmin1(oncoprotein) in 
hepatocarcinoma cells,promotes 
gastric cancer invasion and metastasis 
by targeting tumor suppressor 
EPB41L3,negatively correlated with 
oncogene c-myc, targets tumor 
suppressor FBW7, that targets 
oncoproteins like cyclin E, c-myc for 
degradation, induces GLUT4 
expression 
(Wong, Lung et al. 
2008; Lu, Buchan et 
al. 2010; Xu, 
Sengupta et al. 2010; 
Li, Zhang et al. 
2011; Zhao WY 
2011 Feb) 
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miRNA 27a 0.043 down-
regulation 
0.022 regulates basal transcription by 
targeting the p44 subunit of general 
transcription factor IIH that display 
activities involved in transcription and 
DNA repair processes. 
 
(Portal 2011) 
miRNA 29a 0.139 down-
regulation 
0.035 tumor suppressor, regulates the 
expression of numerous proteins and 
reduces the invasiveness and 
proliferation of human carcinoma cell 
lines 
 
(Muniyappa, 
Dowling et al. 2009) 
miRNA 
301a 
0.027 down- 
regulation 
0.011 oncogenic role in breast 
cancer,controls cell proliferation, 
clonogenicity, migration, invasion, 
tamoxifen resistance, tumor growth, 
and microvessel density 
 
(Shi, Gerster et al. 
2011) 
miRNA 30c 0.044 down- 
regulation 
0.010 independent predictor of clinical 
benefit of endocrine therapy in 
advanced estrogen receptor positive 
breast cancer 
 
(Antony Rodriguez 
2004) 
miRNA 378 0.017 down- 
regulation 
0.025 oncogenic, promotes cell survival, 
tumor growth, and angiogenesis by 
targeting SuFu and Fus-1 expression 
 
(Lee, Deng et al. 
2007) 
miRNA 429 0.055 down- 
regulation 
0.012 modulates expression of c-myc, 
playes important role in pathogenesis 
of gastric carcinoma 
 
(Sun, Wang et al.) 
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miRNA 708 0.011 down- 
regulation 
0.002 tumor suppressor role, induces 
apoptosis and suppresses 
tumorigenicity in renal cancer cells 
 
(Saini, Yamamura et 
al. 2011) 
miRNA 7a 0.047 down-
regulation 
0.03 inhibits Proliferation of Human 
Prostate Cancer Cells in vitro and in 
vivo by targeting E2F2 and CCND2 
 
(Dong, Meng et al. 
2010) 
miRNA 92a 
 
 
 
 
 
 
 
 
0.088 down- 
regulation 
0.04 MYCN-regulated miRNA-92 inhibits 
secretion of the tumor suppressor 
DICKKOPF-3 (DKK3) in 
neuroblastomas 
(Haug, Henriksen et 
al. 2011) 
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Figure 4.6 Differential expressions of miRNAs in Zk-Ob distal colonic mucosa 
versus Zk-Ln distal colonic mucosa. miRNA abundance in the samples was 
normalized using miRNA 4.5s_V1 as endogenous control.The abundance of each of 
the candidate miRNAs is represented as linear RQ or fold change of Zk-Ob distal 
colonic mucosa compared to Zk-Ln distal colonic mucosa (reference sample). P-
values are calculated using student t-test application of DataAssist software v3.0 
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Table 4.5- Significantly up-regulated miRNAs in Zk-Ob distal colon compared to Zk-Ln distal colon 
mi RNA Fold 
change 
Direction Adjusted 
P value 
Cellular function/target Reference 
miRNA 
142-5p 
23.12 up-
regulation 
           
0.005 
regulates target genes in several 
oncogenic signal pathways, such as TP53, 
MAPK, Wnt and vascular endothelial 
growth factor. 
 
(Zhang, Yan et al. 2011) 
miRNA 
146b 
9.84 up-
regulation 
          
0.021 
supresses NF-κB activity in breats cancer 
cells,expressed in response to rising 
inflammatory cytokine levels as part of 
negative feed back loop that restrains 
excessive senescence associated secretory 
phenotype. 
 
(Bhaumik, Scott et al. 
2008; Dipa Bhaumik1 
2009) 
miRNA 150 21.64 up-
regulation 
          
0.018 
tumor suppressor in malignant lymphoma, 
increases the incidence of apoptosis and 
reduced cell proliferation, directly 
downregulated expression of DKC1 and 
AKT2, reduced levels of phosphorylated 
AKTser473/4 and increased levels of tumor 
suppressors such as Bim and p53. 
 
(Watanabe, Tagawa et al. 
2011) 
miRNA 218 25.78 up-
regulation 
          
0.013 
Targets EGFR  that regulates NF-κB 
activity and is associated with apoptotic 
response, tumor suppressor activity in 
lung squamous cell carcinoma, targets 
mTOR 
 
(Davidson, Larsen et al. 
2010; Gao, Zhang et al. 
2010; Uesugi, Kozaki et 
al. 2011) 
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miRNA 223 20.65 up-
regulation 
          
0.029 
Targets starthmin1 (oncoprotein) in 
hepato carcinoma cells, promotes gastric 
cancer invasion and metastasis by 
targeting tumor suppressor EPB41L3, 
negatively correlated with oncogene c-
myc, targets tumor suppressor FBW7, that 
targets oncoproteins like cyclin E, c-MYC 
for degradation, induces GLUT4 
expression 
 
(Wong, Lung et al. 2008; 
Lu, Buchan et al. 2010; 
Xu, Sengupta et al. 2010; 
Li, Zhang et al. 2011; 
Zhao WY 2011 Feb) 
miRNA 29b 2.45 up-
regulation 
0.029 Induces global DNA hypomethylation by 
directly targeting DNMT1 
(Garzon, Liu et al. 2009) 
 
 
miRNA 9 
 
 
26.29 
 
 
up-
regulation 
 
 
0.043 Regulates Neurogenesis in Mouse Telen 
cephalon by Targeting Multiple 
Transcription Factors E-cadherin 
(encoded by CDH1) is a direct target of 
miR-9. 
 
(Mikihito Shibata1 2 
March 2011),(Almeida, 
Reis et al. 2010) 
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Discussion   
The blood plasma results indicate elevated levels of inflammatory cytokines like IL-
1α, IL-6, chemokines like MCP and cellular adhesion molecules like ICAM and E-
selectin, in Zk-Ob compared to Zk-Ln. Obesity is a patho-physiological condition 
that shows heightened inflammatory activity. Early feature of inflammation is the 
release of chemokines like MCP. These factors increase the expression of interstitial 
and vascular cellular adhesion molecules like ICAM and E-selectin that attracts 
monocytes and immune cells. Chemokines like MCP also induce the proliferation 
and pro-inflammatory gene activation producing cytokines like IL-1α, IL-6, IL-18 
etc. Other factors that stimulate gene expression of pro-inflammatory cytokines in 
obese state are RONS, oxidized lipids, free fatty acids. 
Optimising method of miRNA isolation, detection and quantification using Zucker 
rat tissue was the first aim which was achieved using Zk-Ob and Zk- Ln liver tissue. 
The study showed that several miRNAs were differentially expressed in Zk-Ob liver 
compared to Zk-Ln (control) liver. Out of these, 20 miRNAs were significantly up-
regulated, prominent among those were miRNA 137, miRNA 183, miRNA 199-3p, 
miRNA 199-5p, miRNA 200c, miRNA 218, miRNA 223 and miRNA 429. miRNA 
137 is known to be highly expressed in chronically inflammed model of colon 
cancer. (Necela, Carr et al. 2011) Target prediction and pathway analysis suggests 
that this miRNAs regulates signaling pathways related to MAPK, PI3K, WNT, and 
TGF-β, all of which are known to be involved in transformation. In hepato-
carcinoma cells (HCC), miRNA 183, inhibits apoptosis by targeting programmed cell 
death 4 protein (PDCD4) .(Jipeng Li 2010) miRNA 199-3p target mTOR and c-Met 
in HCC.(Fornari, Milazzo et al. 2010) miRNA 199-5p targets discoidin domain 
receptor1 in HCC.(Qingli Shen1 2010) Similarly miRNA 200c, miRNA 218, miRNA 
223 and miRNA 429 have roles either as oncogenes or tumor suppressor or pathways 
related to inflammation, apoptosis, cell growth, cell cycle etc.(Table 4.6) It seems 
that obesity has a profound effect on the expression levels of these miRNAs. The 
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underlying factors of obesity that might be regulating the expression of these 
miRNAs remains to be seen.  
The primary objective of second and third aim was to use miRNA as a molecular tool 
to understand the regional differences in the colon under control and obese 
conditions. The findings of the present study demonstrated that both the anatomical 
regions of the colonic tissue as well as the physiological state of the animal 
influenced the miRNA expression pattern. However, obesity seems to be the 
dominating factor that influences the expression of miRNA in the two regions of the 
colon. Indeed, a selected group of miRNAs showed significant differential 
expression in proximal versus distal colon in both control (lean) as well as obese 
group. However, we were unable to identify common miRNAs that showed similar 
expression pattern in both the groups. Hence, we can conclude that though proximal 
and distal colonic regions show differential expression of miRNAs in the individual 
groups which coincides with the concept of these two regions of colon being 
biologically separate organs, we cannot say the same when comparing one genotype 
with another. On the other hand, obesity was found to have a profound effect on the 
expression pattern of miRNAs in proximal and distal colon. The miRNA that stood 
out in the study, as being regulated differentially in proximal and distal colon by 
obesity factor, is miRNA 223. This miRNA was significantly up-regulated in the 
proximal colon compared to distal in the control lean group. However, in obese 
group, the same miRNA was down-regulated significantly in the proximal colon 
compared to distal. Obesity seems to be influencing the expression of miRNA 223 in 
such a way that it is highly expressed in the distal colonic region and has a very low 
expression in proximal colon. There were several other miRNAs that seemed to be 
influenced by obesity such that expression is drastically altered in the two regions of 
the colon. However, they were not significant and hence not included. It would be 
interesting to find out the factors associated with obesity that could be playing a role 
here. Pro-inflammatory cytokines like IL-6, IL-1α, chemokines like MCP and 
adhesion molecules like ICAM, E-selectin which were found elevated in obese group 
when compared to lean (control) might be involved in regulation of miRNA 
expression in site specific manner.  
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There were 16 miRNAs shortlisted from all the analysis that was found to be 
significantly up or down-regulated. (Table 4.6) Target prediction of these miRNAs, 
using a combination of bioinformatics tool like miRanda, PicTar and Target Scan, 
indicated their role in inflammation, cell proliferation, cell growth, apoptosis, DNA 
damage and repair etc . These findings suggest that the molecular make up of the 
tissue is profoundly affected by genotype and tissue biology.  
miRNA 218 was found to be influenced by obesity so that its expression is up-
regulated significantly in the distal colon under obese conditions. It has been 
experimentally proven that miRNA 218 has tumor suppressor activity in squamous 
cell carcinoma, where it may directly or indirectly target MYC and SRC oncogenes. 
(Davidson, Larsen et al. 2010)  Interestingly, one of the several targets of miRNA 
218, as found by miRanda bioinformatics tool was CDC 27 (cell division cycle 
protein 27 homologue) . This protein is a part of the anaphase promoting complex 
subunit3, a cell cycle-regulated E3 ubiquitin ligase that controls progression through 
mitosis and the G1 phase of the cell cycle. The APC/C complex acts by mediating 
ubiquitination and subsequent degradation of target proteins. miRNA 218 binds to 
the 3’UTR of this cell cycle protein, hence has an oncogenic role. 
miRNA 223 was down-regulated in the proximal region of the colon under obese 
conditions. In liver the expression was 46 fold high in the obese group compared to 
control lean liver. miRNA  223 is known to have tumorigenic functions in hepato-
carcinoma. Overexpression of miRNA 223 in mouse embryonic fibroblasts cell lines 
lead to reduced expression of tumor suppressor FBW7, which targets oncogenes like 
cMYC and cyclinE for ubiquitination and degradation.(Xu, Sengupta et al. 2010) It 
has been found to be negatively correlated with cMYC oncogene in hepato-
carcinoma (Zhao WY 2011 Feb). Interestingly, p53 was also found to be one of the 
targets of miRNA 223, though not experimentally validated. (Source: Uniprot/ 
SWISSPROT ; Acc : P10361). Other predicted target genes identified by more than 
one algorithm were myotrophin (Mtpn), Ras related protein rab-10 (Rab10), nuclear 
factor IA (NfIa), myocyte enhancer factor 2c (Mef2c), and insulin-like growth factor 
1receptor (Igf1r). Glut4 could be a direct targetof miR-223 across species, possible 
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through the interaction of multiple target sites. Over-expression of miR-223 in vitro 
inhibited insulin-stimulated Akt and GSK3b phosphorylation in cardiomyocytes. 
miRNA 223 is also known to induce the expression of GLUT4 (Glucose transporter4)  
and increases the basal glucose uptake in cardiomycetes.(Lu, Buchan et al. 2010)  
miRNA 199-5p showed down-regulation in the proximal colon compared to distal 
colon of both lean and obese group. However, liver showed significant up-regulation 
(16 fold) in obese rat compared to control lean rat. This might be because of 
independent mechanisms of miRNA regulation in liver and colon. In hepato-
carcinoma (HCC) tumors, the under expression of miRNA 199-5p, which happens 
via hypoxia inducible factor (Hif1α) , is inversely correlated with survival and 
directly with malignancy of  HCC. 
 miRNA 125-5p showed similar trend. i.e down-regulation in proximal region of the 
colon under obese condition and up-regulation in obese liver. miRNA 125-5p is 
known to modulate inflammatory response and lipid uptake in macrophages and 
monocytes. (Chen, Huang et al. 2009). miRNA 125-5p directly targets oxysterol 
binding protein related protein 9(ORBP-9) , which is a cholesterol transfer protein 
that regulates golgi-structure and function.(Ridgway 2009 March 1) ORBP9 
maintains the integrity of the early secretory pathway by mediating transport of 
sterols between the ER and trans-Golgi/TGN. Down-regulation of ORBP-9 by 
miRNA 125-5p, causes Golgi fragmentation, inhibition of vesicular somatitus virus 
glycoprotein transport from the ER and accumulation of cholesterol in endosomes 
/lysosomes.(Ridgway 2009 March 1)  
miRNA 132 also shows significant down-regulation in proximal colon compared to 
distal colon under obese condition. It is highly expressed in liver. In the brain, 
miRNA 132 directly targets Acetylcholinesterase (AChE) attenuating inflammation 
by reducing AChE amounts.(Shaked, Meerson et al. 2009). In pancreatic 
adenocarcinoma, miRNA 132 acts as oncogene by targeting tumor suppressor 
Retinoblastoma protein (pRb). 
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miRNA 183 showed significant differential regulation only in the obese group. In 
Zk-Ob rats, it was down-regulated 23 fold times in proximal colon compared to 
distal colon. In the liver tissue, the expression was 7 fold more in the obese group 
compared to the lean group. miRNA 183 is overexpressed in several cancer types eg- 
colon cancer, synovial sarcoma . It targets the tumor suppressor EGR1 and 
PTEN.(Sarver, Li et al. 2010).  
miRNA 191 shows significant down-regulation in proximal colon compared to distal 
colon in the obese group. It is up-regulated in the obese liver (185 fold) compared to 
lean liver .miRNA 191 targets MDM4 which down-regulates p53.(Wynendaele, 
Böhnke et al. 2010) In hepato-carcinoma, miRNA 191 has an oncogenic role where 
they increase cell proliferation  and inhibits apoptosis. (Elyakim, Sitbon et al. 2010)  
miRNA 191 does show a region specific difference in expression and is induced 
under obese conditions which might the factor regulation its differential expression. 
miRNA 301a showed very high expression in distal colon compared to proximal 
colon under obese conditions. miRNA 378 enhances cell survival, tumor growth and 
angiogenesis by targeting two tumor suppressors Sufu and Fus-1 (Lee, Deng et al. 
2007)  in a normal cell. It has been reported that over-expression of miRNA 378 
during adipogenesis increases triacylgylcerol accumulation due to increased de novo 
lipogenesis. Interestingly, miR-378/378∗ is located within the peroxisome  
proliferator-activated receptor gamma(PPAR-γ) coactivator-1 beta gene and is 
transcribed during adipocyte differentiation . 
 Other miRNAs like miRNA 708, 92a, 15b and 21 expressions were also 
significantly altered in the two different regions of the colon under obese conditions. 
Some of them were exclusively expressed in colon and not liver. miRNA 708 
induces apoptosis . In renal cancer it targets the regulators of  E-cadherin such as 
ZEB2  and BMI1, suppresses epithelial to mesenchymal transition(EMT) and hence 
acts as a tumor suppressor.(Saini, Yamamura et al. 2011). In liver miRNA 92a did 
not show any significant differential regulation in obese versus lean. Among the 
miRNAs that were expressed at lower levels in proximal colon under obese 
conditions, miRNA 21 stands out as an important miRNA . This miRNA has been 
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extensively studied as a major player in inflammation and inflammation related 
disorders including cancer. Hence its high expression in liver was well expected. 
However its downregulation in proximal colon compared to distal shows how distal 
and proximal colon stand as distinct organs with independent mechanisms of gene 
regulation. Pro-inflammatory cytokines like IL-6, activate STAT-3 transcription 
factor, which directly binds to the promoter of miRNA21 and activates it. miRNA 21 
targets tumor suppressors like PTEN, leading to increased NF-κB activity, which 
promotes cell survival and cell proliferation. (Iliopoulos, Hirsch et al. 2009)  PTEN 
is a tumor suppressor gene encoding a phosphatase that regulates cell cycle, Akt and 
p53 activity. Tropomyosin 1 (TPM1) and programmed cell death 4 (PDCD4) are 
other tumor suppressors targeted by miRNA21. miRNA 21 expression has been 
correlated as a part of inflammatory response in many cancers including colon 
cancer. IL-6 is thought to drive the expression of miRNA 21 in a STAT dependent 
manner. (Lu, Munitz et al. 2009) There is also a predicted binding site for miR-21 in 
the 3′ untranslated region(3’UTR) of IL-12a as indicated by Targetscan and 
miRanda. Aberrant over-expression of miRNA 21 has been attributed to activated 
EGFR signaling. (Seike, Goto et al. 2009) miRNA 21 has strong connection with 
inflammation and hence its up-regulation in obese conditions both in liver as well as 
colon, is expected. However, the role of obesity associated inflammation in 
regulating the differential expression of miRNA 21 in colon is not clear at this point. 
In addition to the miRNAs discussed in the preceeding section a number of miRNAs 
such as 29, 29b, 30c and 34a were also found altered in different colonic regions 
under obese conditions. 
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Table 4.6- Summary of miRNAs showing significant differential regulation in Zk-Ob versus Zk-Ln and proximal 
versus distal colonic mucosa 
micro 
RNA 
Physiolo
gical 
state 
Colon/liv
er 
Reference 
sample 
Fold 
change/direction 
Biological function 
miRNA 218  Lean proximal 
colon 
distal colon 130 X up-
regulation 
tumor suppressor activity in squamous 
cell carcinoma, targets EGFR, targets 
mTOR 
 
obese distal 
colon 
lean distal 25 X up-regulation  
 
obese  liver lean liver 8X up-regulation 
 
 
 
 
miRNA 223 
 
 
Lean 
 
 
proximal 
colon 
 
 
distal colon 
 
 
41 X up-regulation acts as tumor suppressor by targeting 
stathmin1 oncoprotein, targets tumor 
suppressor EPB4IL3, negatively 
correlated with oncogene c-myc, targets 
tumor suppressor FBW7, which targets 
oncogenes like cMYC and cyclin E for 
ubiquitination and degradation, induces 
GLUT4 ( glucose transporter4) 
expression 
 
 
obese proximal 
colon 
distal colon 42 X down-
regulation 
 
 
obese  proximal 
colon 
lean 
proximal 
46 X down-
regulation 
 
 
obese  distal 
colon 
lean distal 34 X up-regulation  
 
obese liver lean liver 8 X up-regulation 
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miRNA 
199-5p 
obese proximal 
colon 
distal colon 312 X fold down-
regulation 
tumor suppressor in hepato-cellular 
carcinoma, oncogenic in medullo-
blastoma tumor cells 
 
obese  proximal 
colon  
lean 
proximal 
57 X down-
regulation 
 
 
obese liver lean liver 16 X up-regulation 
 
 
miRNA 
125a-5p 
obese proximal 
colon 
distal colon 208 X down-
regulation 
targets oncogene ERBB2 in gastric 
carcinoma cells, regulates inflammatory 
response and lipid uptake in 
monocytes/macrophages. 
 
obese  proximal 
colon 
lean 
proximal 
116 X 
downregulation 
 
 
Obese liver lean liver 6 X upregulation 
 
 
miRNA 132 Obese proximal 
colon 
distal colon 102 X down-
regulation 
Oncogene, targets pRb tumor suppressor 
in pancreatic cancer, Potentiates 
Cholinergic Anti-inflammatory Signaling 
by targeting acetylcholinesterase 
 
 
Obese proximal 
colon 
lean 
proximal 
23 X down-
regulation 
 
 
obese liver lean liver 7 X up-regulation  
 
miRNA 183 obese proximal 
colon 
distal colon 30 X down-
regulation 
oncogene, promotes cell migration 
 
obese liver lean liver 12 X up-regulation  
 
mi RNA 
191 
obese proximal 
colon 
lean 
proximal 
185 X down-
regulation 
oncogene, promotes cell proliferation and 
inhibits apoptosis, tumor suppressor 
targets MDM4 
 
obese liver lean liver 4 X up-regulation  
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mi RNA  
301a 
obese proximal 
colon 
distal colon 196 X down-
regulation 
oncogenic role in breast cancer 
 
obese proximal 
colon 
lean 
proximal 
colon 
37 X 
downregulation 
 
 
 
mi RNA 
378 
obese proximal 
colon  
distal colon 25 X down-
regulation 
oncogenic , promotes cell survival and 
tumor growth 
 
obese proximal 
colon 
lean 
proximal 
40 X down-
regulation 
 
 
 
mi RNA 
708 
obese proximal 
colon 
distal colon 104 X down-
regulation 
 
tumor suppressor, induces apoptosis 
 
obese  proximal lean 
proximal 
526 X down-
regulated 
 
 
 
miRNA 92a obese proximal 
colon 
distal colon 27 X down-
regulation 
tumor suppressor, controls angiogenesis 
in leukemia 
 
obese proximal 
colon 
 
lean 
proximal 
25 X down-
regulated 
 
miRNA 15b obese proximal 
colon 
lean 
proximal 
24 X down-
regulated 
oncogenic role in malignant melanoma 
 
obese Liver lean liver 7 X up-regulation 
 
 
miRNA 21 obese proximal 
colon 
distal colon 20 X down-
regulation 
oncogenic role, targets PTEN 
 
obese liver lean liver 5 X up-regulation 
 
 
miRNA 29b obese distal 
colon 
lean distal 2 X up-regulation both oncogenic and tumor suppressor 
rolerole, targets DNMT 
 
lean proximal distal colon 10 X up-regulation  
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colon  
 
miRNA 30c lean  proximal 
colon 
distal colon 16 X up-regulation tumor suppressor  
 
obese proximal 
colon 
lean 
proximal 
99 X down-
regulation 
 
 
 
miRNA 34a  obese proximal 
colon 
distal colon 123 X down-
regulation 
p53 dependent  tumor suppressor, 
targets CDK4/6, E2F5, BcL2, SIRT1 
(negative regulator of apoptosis under 
stress conditions) 
 
obese liver lean liver 3 X up-regulation  
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CHAPTER 5 
CONCLUSION AND RECOMMENDATION 
 
When one looks at an overall trend it is apparent that miRNAs are expressed in a 
tissue specific manner. Differential miRNA expression in distal and proximal colon 
of both lean and obese group strengthens the molecular evidences supporting the idea 
of existence of proximal and distal colon as separate organs. However, obesity seems 
to be significantly altering the pattern of miRNA expression in these two regions 
when compared with control lean group. Several miRNAs that showed up-regulation 
in distal colon compared to proximal colon in control lean group, show completely 
reverse trend in the obese group. The results obtained demonstrated that obesity 
seem to profoundly affect the expression levels of several miRNAs. Moreover, the 
findings also demonstrated that distinct regional differences exist in the colon with 
respect to expression levels of miRNA. The miRNAs that showed significant 
changes are oncogenic as well as tumor suppressors in cancerous cells and also have 
role in apoptosis, cell growth and differentiation. The findings of the present research 
supports the hypothesis that selected  miRNAs could serve to distinguish molecular 
differences among tissue types and that colonic regions expressing different miRNAs 
expression pattern and levels further confirm that these sites are  biologically 
different entities. These differences may in part be responsible for emergence and 
selection of preneoplastic lesions with different mutations and growth rates. 
However, physiological state such as obesity in this case, cannot be overlooked 
especially when it seems to be altering the miRNA expression pattern in the different 
regions of the colon, in such a significant manner. 
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Summary and Future research 
The findings of the present research have provided a strong foundation to further explore 
the role of miRNAs in colon carcinogenesis. Whether some of these miRNAs are 
secreted in the blood to detect the presence of an early disease state remains to be seen. 
Role of selected miRNAs particularly the miRNAs involved in pathways like 
inflammation, oxidative stress, cholesterol biosynthesis, DNA damage, repair and 
apoptosis will be of interest. In this study, we have focused on the expression of miRNA 
in distal versus proximal colon in obese model. In our study we could not identify 
common miRNAs which could serve as biomarkers for distal and proximal colon, in both 
lean and obese group. However, we conclude that proximal and distal colon show distinct 
pattern of miRNA expression which depends on the host’s physiology. Our results 
indicate that miRNA expression is indeed influenced by obesity and also show site 
specific variation in colon. In future, the connection between obesity and colonic region 
specific miRNA expression needs to be validated. Also, it would be interesting to see if 
the pattern of miRNA expression is the same in the different stages of colon cancer such 
as ACF, adenoma and adenocarcinoma. The study of underlying mechanisms connecting 
obesity with miRNA expression in proximal versus distal colonic tumor will give a 
deeper insight into the complexity of colon carcinogenesis. 
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APPENDICES 
 
APPENDIX A 
 
A.1      Blood Plasma analysis of Zk-Ob and Zk-ln rats 
Commercially available assay using Luminex liquid antibody bead array technology was 
used to measure a panel of cytokines, inflammatory biomarkers and adhesion molecule 
endpoints in plasma, e.g intercellular adhesion molecules(ICAM), E-selectin, monocyte 
chemoattractant protein ( MCP ), IL-1α, IL-6 according to manufacturer’s instructions. 
(Lincoplex, Millipore Bioplex and BioRad). Values   are  mean ± SE, n=4 samples per 
group. 
 
A.2      Results 
      
      
Figure 1- Plasma  levels of  ICAM-1 in Zk-Ob and Zk-Ln (control)  
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Figure 2- Plasma levels of E-selectin in Zk-Ob and Zk-Ln (control) 
            
 
Figure 3- Plasma levels of MCP-1 in Zk-Ob and Zk-Ln(control) 
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Figure 4- Plasma levels of IL-1α in Zk-Ob and Zk-Ln(control) 
  
 
Figure 5 – Plasma levels of IL-6 in Zk-Ob and Zk-Ln (control) 
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APPENDIX B 
 
B.1 Reaction Components for  cDNA synthesis for miRNA quantification 
 
Template miRNA 10-20 ng 
miScript RT buffer(5X)* 2µl 
miScriptReverse Transcriptase 
Mix 
1µl 
RNase free water variable 
Total reaction volume 10µl 
 
B.2 Real time PCR for miRNA quantification 
2x Quanti Tect SYBR Green PCR 
Master Mix 
 10µl 
10x mi Script Universal Primer  2µl 
10x mi Script Primer Assay 2µl 
Template cDNA 3 ng/reaction 
RNase free water variable 
Total volume 20 µl 
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B.3 Cycling conditions for real-time PCR for miRNA quantification 
 
 B.4 Components for cDNA synthesis for miRNA array 
For each reaction, the following components were added in a sterile PCR tube  
Small RNA – 50-400 ng of mi RNA enriched fraction 
5x miRNA RT Buffer 2  - 2.0 µl   
RT Enzyme Mix - 1.0 µl    
Nucleotide Mix - 1.0 µl    
RT primer + ERC mix – 1.0 µl 
RNase-free H2O to a final volume of  10.0 µl 
 
 
B.5 Components for real time PCR step in array experiment 
 
2X RT2 SYBR Green qPCR Mastermix –1275 µL 
Diluted first strand reaction-100 µL 
RNase free H2O- 1175 Μl 
Total volume- 2550 µL 
 
Step Time Temperature Specifications 
PCR initial activation step 
3-step cycling: 
Denaturation 
Annealing 
Extension 
Cycle number 
15 min 
 
 
15 sec 
30 sec 
34 sec 
40 cycles 
95°C 
 
 
94°C 
55°C 
70°C 
HotStarTaq DNA Polymerase is 
activated by this heating step. 
 
 
 
Fluorescence data collection. 
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B.6 Cycling conditions for real time PCR for array experiment 
 
Cycles Duration Temperature 
1 10 minutes 95°C 
 
40 
15 seconds 
40 seconds 
32 seconds 
 
95°C 
60°C 
72°C 
 
 
B.7 RT2 miRNA array layout 
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